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Human breast milk contains essential nutrients and immunological factors that are critical for the 
health and development of infants.  The benefits of breast-feeding have been studied extensively, 
and research has shown that breastfed infants have a decreased risk of infections and illnesses.  
There are many instances when mothers are unable to provide their own milk, which is the case 
with many prematurely born infants.  Breast milk banks and facilities that process human milk 
provide an alternative solution to synthetic or animal derived infant formula, allowing babies to 
receive the benefits of human breast milk.  There are many drugs that can pass into a woman’s 
breast milk and cause possible harm to an infant.  It is important that donor milk be screened for 
drugs-of-abuse in order to prevent this from occurring.  The purpose of this study was to 
optimize and validate enzyme-linked immunosorbent assays (ELISA) for the detection of a 
seven-drug panel in human breast milk.  The following Neogen Corporation kits were utilized: 
Amphetamine Ultra, Benzodiazepine Group, Cocaine/Benzoylecgonine (BZE), Cotinine, Opiate 
Group, Oxycodone/Oxymorphone, and THC.  Sample dilutions that minimized breast milk 
matrix interference were determined, and cutoff leve s for each assay were proposed based on 
the linear range of the assay.  The seven-drug panel was validated through the assessment of 
drift, precision, and accuracy.  The Cocaine/BZE and Opiate Group cutoffs were increased from 
30 to 50 ng/mL after several false negative results were obtained during the accuracy portion of 
the validation.  The ELISA assays were validated at two different sites, and the robustness of the 










 Human breast milk contains essential nutrients and immunological factors that are critical 
for the health and development of infants (Leaf & Winterson, 2009; Marchei, et al., 2011).  The 
benefits of breastfeeding have been studied extensiv ly, and research has shown that breastfed 
infants have a decreased risk of infections and illesses (American Academy of Pediatrics, 2012; 
Ito & Lee, 2003; Leaf & Winterson, 2009; Marchei, et al., 2011).  There are many instances 
when mothers are unable to provide their own milk, which is the case with many prematurely 
born infants (Boyd, Quigley, & Brocklehurst, 2007; Ganapathy, Hay, & Kim, 2011; Sullivan, et 
al., 2010).  Human milk banks and facilities that produce human-milk-based nutritional products 
are able to provide an alternative solution to synthetic or animal derived infant formula, which 
allows babies to receive the benefits of human breast milk (Bertino, et al., 2009; Boyd, et al., 
2007; Simmer & Hartmann, 2009; Wojcik, Rechtman, Lee, Montoya, & Medo, 2009).  While it 
is important that all breastfeeding mothers avoid drugs and other harmful substances that could 
pass into their milk and affect the health of their babies, it is essential for milk banks and 
facilities that process human milk to ensure that tey are supplying drug-free milk to hospitals 
(Marchei, et al., 2011).  Due to the demand of human ilk and milk products, milk banks and 
manufacturing facilities are focused on increasing processing efficiency.  One of the ways that 
this can be achieved is by utilizing a high-throughput screening method for drugs-of-abuse that 
has a short turn-around time.   
 Enzyme-linked immunosorbent assays (ELISA) have been used extensively in forensic 
toxicology settings for the purposes of screening for the presence of drugs (Elian, 2003; Hand & 
Baldwin, 2008).  Screening tests are typically lessxpensive and time consuming than 
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confirmation tests (Gaensslen, Harris, & Lee, 2008).  A screening test has the ability to detect 
whether a particular substance may be present in a sample, or if the substance is not present 
(Smith, 2003).  Confirmation testing can then be performed on samples that screen positive, 
which removes the need to perform a complete analysis on each submitted sample (Gaensslen, et 
al., 2008; Smith, 2003).  ELISA assays are easy to use, have a short turn-around time, can be 
automated for high-throughput scenarios, and have the ability to detect low levels of drug (Elian, 
2003; Hand & Baldwin, 2008; Smith, 2003).    
Purpose 
The use of ELISA assays for drug screening purposes has primarily been reserved for 
commonly tested body fluids, such as blood, urine, and saliva.  In situations where testing is to 
be performed in a matrix that differs from that for which an ELISA has been validated, good 
science dictates that the kit be validated to demonstrate its efficacy in the new matrix (Hand & 
Baldwin, 2008).  This is of particular importance in the case of breast milk as it contains natural 
emulsifying agents that possess detergent-like activity, and “may interfere with antibody-antigen 
reactions which take place in immunoassay screening tests” (Kerrigan & Goldberger, 2000).  
The purpose of this project was to optimize and validate a method for the screening of a seven-
drug panel in human breast milk using ELISA assays. 
Significance of the Study 
 The majority of human milk and human-milk-based products supplied to pre-term infants 
originate from human milk banks and processing facilities (Bertino, et al., 2009; Boyd, et al., 
2007; Ganapathy, et al., 2011; Simmer & Hartmann, 2009; Wojcik, et al., 2009).  These infants 
typically have weak immune systems and are at risk of developing many different kinds of 
diseases (Ganapathy, et al., 2011; Sullivan, et al., 2010).  It is critical that these babies be 
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provided human milk in order to nourish their still-developing bodies and immune systems 
(Boyd, et al., 2007; Sullivan, et al., 2010).  It is also essential that these babies not be exposed t 
any drugs that could cause further harm (Berlin, 2003; Lozano, et al., 2007; Marchei, et al., 
2011).  Screening for drugs in breast milk is an important public health issue, because providing 
drug-free human milk to infants has a positive effect their health both immediately and as they 
age.  This translates to babies, children, and adults who need less heath care, and are less of an 
economic strain on the health care system (Ito & Lee, 2003).  From a business standpoint, milk 
banks and processing facilities are more likely to be able to sell their products if they can 
demonstrate that they have a robust screening process for their donors, which includes a drugs-
of-abuse screening (Polifka, 1998).   
Seven-Drug Panel 
The literature was reviewed to determine the dangers of exposing infants to breast milk 
containing drugs.  Based on this research and the prevalence of use within the general 
population, a drug panel for the following categories of drugs was developed: amphetamines, 
benzodiazepines, cocaine, nicotine, opiates, including oxycodone, and cannabinoids.  ELISA 
assays were assessed for their feasibility of use in the screening of this drug panel in breast milk.  
ELISA kits from Neogen Corporation (Lexington, KY) were evaluated for the development of 
the final seven-drug panel.  The following nine kits were initially evaluated: Amphetamine Ultra, 
Benzodiazepine Group, Cocaine/BZE, Cotinine, Hydromorphone, Methamphetamine/MDMA, 
Opiate Group, Oxycodone/Oxymorphone, and THC.  The Hydromorphone kit was not used for 
the final panel because the Opiate kit demonstrated high cross-reactivity with hydromorphone.  
The Methamphetamine/MDMA kit was not used for the final panel because the Amphetamine 
Ultra kit demonstrated high cross-reactivity with d-methamphetamine, and it was decided that 
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the identification of MDMA (3,4-methylenedioxy-N-methylamphetamine) in breast milk would 
not be pursued for this drug panel.  The final seven-drug panel consisted of the following seven 
Neogen kits: Amphetamine Ultra, Benzodiazepine Group, Cocaine/BZE, Cotinine, Opiate 
Group, Oxycodone/Oxymorphone, and THC.   
Definitions 
Absorbance (A): A logarithmic measure of the amount of light absor ed at a particular 
wavelength as the light passes through a sample or substance.  The absorbance of a solution is 
linearly related to the concentration of the absorbing species (K. Cole & Levine, 2009).   
%B/B0: The ratio of the absorbance of a particular sample well (B) to the absorbance of the 
negative well (B0), expressed as a percentage.  B0 contains no analyte, so it is the concentration 
at which maximum absorbance can occur (Hand & Baldwin, 2008; Smith, 2003). 
Calibrator: A calibrator is used to calibrate an assay, and is either prepared from reference 
material or purchased from a suitable vendor (American Board of Forensic Toxicology).  A 
negative calibrator is used to determine an absorbance value that corresponds with no 
analyte/antibody competition.  A cutoff calibrator is used to determine an absorbance value that 
samples will be compared to in order to make positive and negative determinations (Schwope, 
Milman, & Huestis, 2010). 
Coefficient of variation (CV):  The % CV is a ratio of a sample standard deviation to the sample 
mean expressed as a percentage (D'Agostino, Sullivan, & Beiser, 2006). 
Cutoff level: The cutoff level establishes the concentration at which a sample is declared either 
positive or negative for the analyte of interest.  A sample with a concentration greater than the 
cutoff level will be reported out as positive, while a sample with a concentration lower than the 
cutoff level will be declared negative (Hand & Baldwin, 2008; Smith, 2003).  
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Enzyme-linked immunosorbent assay (ELISA):  n ELISA is a biochemical technique used to 
detect the presence of an antibody or antigen in a sample (Hand & Baldwin, 2008; Smith, 2003).   
I-50: The absorbance that is halfway in between the maxi um and minimum absorbance.  It can 
be thought of as the concentration directly between no competition and maximum competition of 
the analyte for the antibody (Schwope, et al., 2010). 
Literature Review 
Benefits of Breastfeeding 
 Human breast milk is ideally suited for the growth and development of human infants 
(Lawrence & Schaefer, 2007).  It contains essential utrients, immunological factors, digestive 
enzymes, growth factors, and enzymes, all of which are critical for an infant’s health and 
development (Leaf & Winterson, 2009; Marchei, et al., 2011).  Breastfeeding has been shown to 
lower the prevalence a wide variety of diseases and co itions.  For infants and toddlers, the risk 
of developing respiratory tract infections, otitis media, gastrointestinal tract infections, 
necrotizing enterocolitis, and sudden infant death syndrome is drastically reduced (American 
Academy of Pediatrics, 2012; Ganapathy, et al., 2011; Singhal, Cole, Fretwell, & Lucas, 2004; 
Sullivan, et al., 2010).  Long-term benefits include a decreased risk of allergic disease, diabetes, 
obesity, atherosclerotic cardiovascular disease, celiac disease, and inflammatory bowel disease 
(American Academy of Pediatrics, 2012; Friguls, et al., 2010, Ito & Lee, 2003).  Babies who are 
breastfed have also demonstrated greater aptitude scor s on developmental and intelligence tests 
(Ito & Lee, 2003; Lawrence & Schaefer, 2007).  Both the American Academy of Pediatrics 
(2012) and the American Dietetic Association (2009) suggest exclusive breastfeeding for six 
months, and then breastfeeding with complementary foods from six to 12 months.  
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Hazards of Maternal Drug Use 
 While very few drugs are absolutely contraindicated during breastfeeding, the adverse 
effects of the majority of drugs and medications on infant health, both short term and long term, 
are not well known.  “Most recommendations on the saf ty of medications during lactation are 
based on theoretical risks, case reports, or single cas  studies that measured breast milk or infant 
serum levels” (Ito & Lee, 2003).  The exact prevalence of drug use by breastfeeding women is 
unknown, but there are several estimates in the literature.  It is estimated that between 0.4 and 
27% of urban American women abuse drugs while pregnant (Kerrigan & Goldberger, 2000).  It 
can be assumed that the majority of these women would c ntinue to abuse drugs while 
breastfeeding.  Ito and Lee (2003) reported that during the first week after delivery, roughly 90% 
of women take some form of medication.  Howard and Lawrence (1999) reported that in a study 
of 14,000 women, 79% had used at least one medication, with an average of 3.3 different drugs, 
during breastfeeding.  In a similar study of 838 breastfeeding women, 80% were taking at least 
one drug, 20% were taking two or more, and 89% of the breastfed infants were younger than 
four months (Berlin & Briggs, 2005).  There are case reports of clinically significant toxicity in 
infants who have been exposed to drugs through breast milk.  However, the amount of data is 
sparse due to the fact that it is difficult to conduct research in breastfeeding women and their 
infants regarding clinical risk assessments of drugs (Friguls, et al., 2010). 
An infant’s exposure to drugs in breast milk depends on a drug’s milk-to-plasma 
concentration ratio, maternal and mammary pharmacokinetics, the amount of milk consumed, 
and the infant’s rate of drug clearance (Begg, 1996; Friguls, et al., 2010; Ito & Lee, 2003).  The 
pharmacokinetic considerations of neonates and young infants are difficult to estimate due to the 
continuous shifting of their ability to absorb, metabolize, and eliminate substances (Atkinson, 
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Begg, & Darlow, 1988).  Drug clearance rates in neonates and young infants are low due in large 
part to the immaturity of their drug elimination systems (Friguls, et al., 2010).  Renal excretion 
of drugs is dependent on the glomerular filtration rate, tubular secretion, and protein binding 
(Atkinson, et al., 1988; Friguls, et al., 2010).  The glomerular filtration rate for a full-term 
neonate is approximately 25% of adult values (Friguls, et al., 2010).  This rate doubles within the 
first two weeks of life and adult levels are reach by three to five months of age (Atkinson, et al., 
1988; Friguls, et al., 2010).  Both protein binding and tubular function are decreased in neonates, 
with adult values being achieved within ten to twelve and seven to nine months respectively 
(Atkinson, et al., 1988).  Both phase I and phase II drug metabolism are impaired in neonates.  
Cytochrome P450 isoenzymes develop at different rates in relation to one another, and between 
infants (Atkinson, et al., 1988; Friguls, et al., 2010).  “Overlapping substrate specificities and 
genetic polymorphisms add complexity to drug biotransformation in infants” (Friguls, et al., 
2010). 
Breast Milk as a Matrix 
 Breast milk is an unconventional matrix for assessing both maternal and neonatal 
exposure to drugs (Marchei, et al., 2011).  Breastfeding women produce an average of 600 to 
1000 mL of milk a day, and an infant typically consumes 150 mL/kg/day (Berlin & Briggs, 
2005; Sagraves, 1997).  The composition of breast milk changes not only as the infant ages, but 
also during the course of a feeding and throughout the day (Kerrigan & Goldberger, 2000; Leaf 
& Winterson, 2009; Sagraves, 1997).  Analytical challenges intrinsic to the extraction of drugs 
from breast milk include its high protein and fat content, along with its continually changing 
composition (Friguls, et al., 2010; Kerrigan & Goldberger, 2000).   
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Drug characteristics affecting the amount of drug excr ted from plasma into breast milk 
include protein binding, ionization, degree of lipophilicity, and molecular weight (Agatonovic-
Kustrin, Ling, Tham, & Alany, 2002; Howard & Lawrence, 1999; Ito & Lee, 2003; Sagraves, 
1997).  Highly protein-bound drugs are less likely to leave the maternal serum and pass into the 
breast milk (Agatonovic-Kustrin, et al., 2002; Howard & Lawrence, 1999; Sagraves, 1997).  The 
maternal characteristics influencing the concentration of a substance in milk depend on the dose 
ingested, duration of consumption, the amount of milk excreted daily, the pH of maternal plasma 
and milk, and the woman’s individual metabolic and physiological characteristics (Agatonovic-
Kustrin, et al., 2002; Howard & Lawrence, 1999; Ito & Lee, 2003; Sagraves, 1997).  The pH of 
human breast milk is slightly more acidic (average pH of 7.1 to 7.2) than plasma (pH of 7.4), 
which favors the passage of alkaline drugs into milk (Agatonovic-Kustrin, et al., 2002; Howard 
& Lawrence, 1999; Sagraves, 1997).  “Typically, a low-molecular weight, un-ionized, lipid-
soluble basic compound that has low plasma protein binding can cross into human milk with 
relative ease” (Sagraves, 1997).   
Excretion of drugs in breast milk mostly occurs by simple passive diffusion, but carrier-
mediated transport and active transport take place for certain drugs (Agatonovic-Kustrin, et al., 
2002; Howard & Lawrence, 1999; Ito & Lee, 2003).  The ratio between the concentration of the 
drug in milk and that in maternal plasma is called the milk-to-plasma (M:P) concentration ratio 
(Begg, 1996; Friguls, et al., 2010; Sagraves, 1997).  While this ratio is extremely useful in 
predicting how likely it is that a drug will concentrated in the breast milk, it is based on the 
assumption “that the milk and plasma concentrations parallel each other throughout the maternal 
dosing interval,” which is not always true (Begg, 1996; Sagraves, 1997).  In general higher M:P 
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ratios indicate that a greater amount of drug is transferred to the breast milk (Howard & 
Lawrence, 1999).  
Specific Drugs 
Amphetamines. 
Amphetamines are among most widely abused compounds by recreational drug users in 
developing countries, and rates of use are reportedly increasing (Bartu, Dusci, & Ilett, 2009; 
Friguls, et al., 2010).  “Methamphetamine is currently the most frequently encountered 
clandestinely produced controlled substance in the U.S.,” due in large part to the ease with which 
it can be synthesized in makeshift laboratories (Moore, 2010).  Amphetamines stimulate the 
central nervous system (CNS) and can produce euphoric effects.  Methamphetamine possesses a 
long half-life, which can be ten times longer than cocaine (Moore, 2010).  Amphetamine has a 
six to 12 hour half-life, with both hepatic and renal clearance contributing to its elimination 
(Friguls, et al., 2010).  Amphetamines and cocaine have similar pharmacokinetic profiles.  They 
are “highly lipid soluble and well absorbed orally, with a bioavailability of approximately 67% 
and a volume of distribution of 3-7 L/kg” (Moore, 2010).  Amphetamines are weak bases with 
relatively low molecular weights, allowing them to easily diffuse “across cell membranes into 
tissues or biological substrates with a more acidic pH than blood, such as milk” (Friguls, et al., 
2010; Steiner, Villen, Hallberg, & Rane, 1984).  Amphetamine has a high milk-to-plasma ratio, 
ranging from 2.8:1 to 7.5:1, which indicates that is concentrated in breast milk (Friguls, et al., 
2010; Steiner, et al., 1984).  Methamphetamine undergoes N-demethylation to amphetamine, 
which is catalyzed by human hepatic cytochrome P450 isoenzyme CYP2D6 (Bartu, et al., 2009; 
Friguls, et al., 2010).  It is primarily excreted in the urine as the parent drug, with up to 45% of a 
single dose being eliminated within 24 hours (Moore, 2010).  Amphetamine is an active 
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metabolite, and accounts for approximately 4-7% of a methamphetamine dose in a 24-hour urine 
sample (Bartu, et al., 2009).     
Bartu et al. (2009) collected urine and milk samples from two mothers who were 
intravenous users of methamphetamine.  Urine was collected four hours after a single dose, and 
milk samples were collected prior to drug use and at two to six hour intervals following the dose, 
for a period of 24 hours.  The urine samples were analyzed by gas chromatography-mass 
spectrometry (GC-MS), while the milk samples were analyzed using high performance liquid 
chromatography (HPLC).  Both the urine and milk samples contained primarily 
methamphetamine and lower amounts of amphetamine.  Th  average methamphetamine 
concentrations in the milk samples collected 24 hours post dosing were 111 µg/L and 281 µg/L.  
The amphetamine concentrations were 4 µg/L and 15 µg/L in the same samples.  These milk 
samples were found to have an average half-life of t n hours for methamphetamine, and 28 hours 
for amphetamine.  The absolute infant doses were calculated to be 17.5 µg/kg/day and 44.7 
µg/kg/day.  Based on this data, the authors recommended that breastfeeding be withheld for 48 
hours following a single recreational dose of methamphetamine (Bartu, et al., 2009).   
Steiner et al. (1984) studied the excretion of amphetamine into the milk of a 
breastfeeding mother with narcolepsy, who was treated daily with 20 mg of amphetamine.  The 
concentration of amphetamine was three times higher in breast milk than in maternal plasma on 
the tenth day following delivery, and seven times higher on the 42nd day after delivery.  This 
supports the theory that alkaline drugs accumulate in breast milk.  Urine samples were collected 
from the nursing infant, and small amounts of amphetamine were detected.  The infant was 
monitored for an additional 24 months, and no adverse ffects were observed or reported 
(Steiner, et al., 1984).  An investigation of the transfer of dexamphetamine into breast milk 
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during treatment for attention deficit hyperactivity disorder was conducted using a high 
performance liquid chromatography-ultraviolet (HPLC-UV) method.  This study found that the 
relative infant dose was <10% of the maternal dose (Ilett, Hackett, Kristensen, & Kohan, 2007).   
The following adverse effects have been reported for in ants breastfed by amphetamine 
users: irritability, poor sleeping pattern, agitation, and crying (American Academy of Pediatrics, 
2001; Friguls, et al., 2010).  Ariagno, Karch, Middleberg, Stephens, & Valdes-Dapena (1995) 
reported the death of an infant breastfed by a methamp etamine user.  The infant’s blood 
concentration contained 39 ng/mL of methamphetamine, a d the authors presented evidence that 
the death was attributable to cardiopulmonary failure caused by exposure to the drug in breast 
milk (Ariagno, et al., 1995). 
Benzodiazepines. 
 Benzodiazepines are frequently prescribed to women duri g pregnancy and after 
childbirth, but long-term therapy should be avoided uring breastfeeding (Friguls, et al., 2010; 
Howard & Lawrence, 1999).  They are CNS depressants, d approximately 30% of 
benzodiazepine use is illicit (Friguls, et al., 2010; Jufer-Phipps & Levine, 2010).  
Benzodiazepines are highly protein-bound, with a volume of distribution of 2 L/kg (Jufer-Phipps 
& Levine, 2010).  Benzodiazepines can be categorized into long-acting, intermediate-acting, and 
short-acting compounds, depending on the length of eir half-life (Friguls, et al., 2010; Howard 
& Lawrence, 1999; Iqbal, Sobhan, & Ryals, 2002; Jufer-Phipps & Levine, 2010).  The long half-
lives of some of these compounds, coupled with an infant’s underdeveloped metabolic and 
excretory function, can lead to measurable amounts of drug in plasma and tissues, such as the 
brain (Friguls, et al., 2010; Howard & Lawrence, 1999; Kerrigan & Goldberger, 2000).  The M:P 
ratios for most benzodiazepines are fairly low, with breast milk concentrations at ten to 20% of 
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the maternal plasma concentrations (Jufer-Phipps & Levine, 2010).  “Because these drugs affect 
neurotransmitter function in the developing CNS, it may not be possible to predict long-term 
neurodevelopmental effects” (Friguls, et al., 2010).  
Alprazolam.   
Alprazolam is an intermediate-acting benzodiazepine that has two active metabolites, 4-
hydroxyalprazolam and α-hydroxyalprazolam, which are known to cross the placenta (Friguls, et 
al., 2010; Iqbal, et al., 2002; Jufer-Phipps & Levine, 2010; Oo, Kuhn, Desai, Wright, & 
McNamara, 1995).  It has a pKa of 2.4, is soluble in methanol and ethanol, insoluble in water, 
and has a bioavailability of approximately 90%.  A single dose of alprazolam will be almost 
completely eliminated with 72 hours (Jufer-Phipps & Levine, 2010).   
Oo et al. (1995) studied the pharmacokinetics of alprazolam and its metabolites in breast 
milk.  Blood and breast milk samples were collected from eight subjects following single oral 
doses of alprazolam, for a period of 36 hours.  These samples were analyzed with HPLC-UV 
following protein precipitation with acetonitrile and solid phase extraction (SPE).  The milk and 
plasma concentrations paralleled one another, and the milk concentrations were found to be 
lower than plasma concentrations, with a M:P ratio of 0.36:1.  Low concentrations of 4-
hydroxyalprazolam were detected in plasma only, while α-hydroxyalprazolam was not detected 
in plasma or milk.  The results of this study suggest that neonatal doses of alprazolam in breast 
milk would be low and are unlikely to result in any adverse effects in the nursing infant (Oo, et 
al., 1995).  However, case studies have been reported where mothers discontinued their use of 
alprazolam during breastfeeding due to adverse effects observed in their infants.  These 
symptoms included restlessness, irritability, and sleep disturbance.  The mothers also noted 
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withdrawal symptoms at the discontinuation of breastf eding (O. Anderson, 1989; Iqbal, et al., 
2002).   
Diazepam.  
Diazepam is a long-acting benzodiazepine with a half-life of approximately 20–50 hours 
in full-term infants (Dusci, Good, Hall, & Ilett, 1990; Friguls, et al., 2010; Iqbal, et al., 2002).  It 
has a pKa of 3.3, is soluble in ethanol, slightly soluble in water, and has an oral bioavailability of 
around 100%.  It undergoes demethylation by the CYP2C19 and CYP3A4 isoenzymes, which 
form its primary metabolite of nordiazepam.  This active metabolite can accumulate in the 
plasma following repeated dosing (Jufer-Phipps & Levin , 2010).  Diazepam and its metabolites 
have been found to possess M:P ratios ranging from 0.2:1 to 2.7:1 (Friguls, et al., 2010).  Due to 
diazepam’s long half-life and slow metabolism in infants, accumulation of both diazepam and its 
metabolites can occur (A. P. Cole & Hailey, 1975; K. Cole & Levine, 2009; Friguls, et al., 2010).   
Cole and Hailey (1975) conducted a study of nine mothers taking diazepam.  Maternal 
milk and blood samples were collected along with neonate blood samples.  Both diazepam and 
N-desmethyldiazepam were detected in breast milk samples and neonate blood samples.  
“Appreciable amounts of active substances were detected in one infant ten days after a single 
dose was given to the mother” during the delivery (A. P. Cole & Hailey, 1975).  Several other 
studies have reported infant sedation and lethargy in breastfed infants whose mothers were using 
diazepam (Friguls, et al., 2010; Iqbal, et al., 2002).  
Cannabinoids. 
Marijuana is the most commonly used recreational drug of abuse around the world, and is 
also prescribed for health reasons (Friguls, et al., 2010; Huestis, 2010).  The frequency of use 
among pregnant women is estimated to be between fiv and 34% (Astley & Little, 1989).  
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Infants can be exposed to marijuana from consuming the milk of mothers who use the drug and 
also from passive inhalation (Friguls, et al., 2010; Liston, 1998).  The principal psychoactive 
compound in marijuana, delta-9- tetrahydrocannabinol (∆9-THC or THC), is highly lipid soluble, 
rapidly distributed into the brain and adipose tissue, has a large volume of distribution, and binds 
extensively to plasma proteins (Friguls, et al., 2010; Garry, et al., 2009; Huestis, 2010; Liston, 
1998).  At low doses, it causes both stimulant and depressant effects, while at high doses it acts 
as a CNS depressant (Huestis, 2010).  The eliminatio  half-life of THC ranges from 20 to 48 
hours, and traces of the drug can remain in the body for four to six weeks.  It is stored in adipose 
tissues for long periods of time (weeks to months), and chronic users may exhibit a longer half-
life of 4 days (Friguls, et al., 2010; Garry, et al., 2009).  Marijuana is concentrated in breast milk 
and has a high M:P ratio of up to 8:1 (Friguls, et al., 2010; Garry, et al., 2009; Liston, 1998).  An 
infant ingests approximately 0.8% of the weight-adjusted maternal intake of one joint (marijuana 
cigarette) during a single breast milk feeding (Friguls, et al., 2010; Garry, et al., 2009).  Infants 
who have been exposed to marijuana through breast milk will excrete THC in their urine for two 
to three weeks (Garry, et al., 2009). 
Animal studies have shown that newborn animals exposed to marijuana in breast milk 
suffered from altered brain cell metabolism due to impaired DNA and RNA synthesis of brain 
cells.  As critical brain development occurs during an infant’s first few months of life, exposure 
to marijuana during this time could negatively affect this process (Garry, et al., 2009; Liston, 
1998).  Case studies have described sedation, reduced muscular tonus, and poor sucking in 
infants who have been exposed to marijuana (Astley & Little, 1989; Garry, et al., 2009).  Astley 
and Little (1989) conducted a study that examined th  relationship between infant exposure to 
marijuana from breast milk, and motor and mental development at 12 months of age.  Of the 136 
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infants assessed, 68 were exposed to marijuana throug  breastfeeding.  This exposure was 
associated with a decrease in infant motor development.  The largest decreases were seen in 
infants who had daily exposure to marijuana during the first month of life (Astley & Little, 
1989).  The analysis of marijuana is human breast milk has only been performed in one study to 
date.  Perez-Reyes et al. (1982) used liquid chromat gr phy-mass spectrometry (LC-MS) to 
study the passage of THC into breast milk and found that moderate amounts of drug were 
excreted in recreational users, but that chronic users accumulated a much greater proportion of 
drug. 
Cocaine. 
 Cocaine is a psychotropic drug with anesthetic prope ties (Chasnoff, Lewis, & Squires, 
1987), and its illicit use in the United States and Europe has steadily increased over the past 
decade (Chasnoff, et al., 1987; Huestis, 2010; Isenschmid, 2010).  The bioavailability varies 
dramatically depending on the route of administration, with 100% bioavailability in intravenous 
doses and 20% bioavailability when the drug is ingested orally (Isenschmid, 2010).  The half-life 
of cocaine is approximately one hour, and it is rapidly excreted into breast milk (Friguls, et al., 
2010; Winecker, et al., 2001).  It is primarily metabolized to benzoylecgonine (BZE) and 
ecgonine methyl ester (EME), and excretion occurs primarily by simple filtration into the urine.  
One to nine percent of cocaine is excreted unchanged, 26-54% is excreted as BZE, 18-41% as 
EME, and 2-3% as ecgonine.  Approximately 64-69% of a single dose will be excreted in the 
urine with three days, with 86% of this amount being excreted with the first day (Isenschmid, 
2010).  Abuse of cocaine can lead to extremely highplasma concentrations (Dickson, et al., 
1994).  Although the M:P ratio has not been established in human, rats were found to have a ratio 
of 7.8:1 (Dickson, et al., 1994; Friguls, et al., 2010).  If human M:P ratios are similarly high, 
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toxic concentrations could easily accumulate in infants.  Dickson et al. (1994) used the 
Henderson-Hasselbach equation to demonstrate that the concentration of cocaine in breast milk 
could be twenty times that of the mother’s plasma levels.   
Several case studies have reported intoxication in breastfed infants exposed to cocaine.  
Chasnoff et al. (1987) reported the admission of a two week old breastfed infant whose mother 
had a history of cocaine and alcohol abuse.  The mother admitted using 0.5 g of cocaine prior to 
breastfeeding her child five times.  The infant quickly became irritable, had vomiting, diarrhea, 
and dilated pupils.  Both the mother’s milk and the infant’s urine were found to contain cocaine 
and BZE.  The milk samples were negative for both ccaine and metabolites 36 hours after the 
last reported cocaine use.  The infant’s urine sample was negative 60 hours after the last reported 
breastfeeding (Chasnoff, et al., 1987).  Winecker et al. (2001) collected breast milk from 11 
mothers who admitted cocaine use, and found that the highest cocaine concentration was 12.1 
µg/mL of breast milk.  The authors concluded that breastfed infants of these mothers could be 
exposed to significant amounts of drug (Winecker, et al., 2001). 
Nicotine. 
 Despite the publicized risks associated with tobacco use, approximately 25-30% of 
women in the U.S. smoke cigarettes during pregnancy (Howard & Lawrence, 1999; Ilett, et al., 
2003).  Nicotine is a toxic substance, with low-level poisoning leading to dizziness, nausea, and 
weakness.  Toxic concentrations can cause tremors, c nvulsions, paralysis of the respiratory 
muscles, and death (Howard & Lawrence, 1999).  Nicotine has a half-life of approximately one 
hour in serum and two hours in breast milk, and is metabolized to cotinine, trans-3-hydroxy 
cotinine and cotinine-N-oxide (Friguls, et al., 2010; Luck & Nau, 1987).  The cotinine serum 
concentration remains constant during a four hour period following smoking (Friguls, et al., 
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2010).  Nicotine has a M:P ratio of around 3:1 (Dahlstrom, Ebersjo, & Lundell, 2004; Friguls, et 
al., 2010; Luck & Nau, 1987).  It has a pKa of 8.0, which causes it to become concentrated as it 
passes into breast milk (Dahlstrom, Lundell, Curvall, & Thapper, 1990; Friguls, et al., 2010).  
The excretion of nicotine and cotinine into breast milk is proportional to the number of cigarettes 
smoked (Dahlstrom, et al., 2004; Dahlstrom, et al., 1990; Friguls, et al., 2010; Luck & Nau, 
1987).  In a study by Dahlstrom et al. (2004), infants of mothers who used chewing tobacco 
while breastfeeding were exposed to higher nicotine concentrations than infants whose mothers 
who smoked cigarettes.   
Infants raised by smokers have been found to have nicoti e and cotinine in their urine, 
with much higher concentrations seen in breastfed infants.  For this reason, it is difficult to 
correlate a maternal M:P ratio with the levels seen in i fants unless they are completely protected 
from passive inhalation (Howard & Lawrence, 1999).  Ilett et al. (2003) found that the absolute 
infant dose of nicotine and cotinine decreased by 70% when breastfeeding mothers used nicotine 
patches instead of smoking.  Many studies have shown that smoking is associated with the 
production of lower volumes of milk (Howard & Lawrence, 1999).  Infants of smoking mothers 
have shown increased rates of infantile colic and respi atory infections, with decreased 
respiratory rates and oxygen saturation following breastfeeding.  A case of nicotine withdrawal 
syndrome was seen in a breastfeeding infant whose mther was a heavy tobacco smoker.  High 
concentrations of nicotine were measured in both the infant’s and mother’s hair, and 128 ng/mL 
of cotinine was detected in samples of breast milk.  The infant demonstrated “spontaneous 
tremors and rigidity for a month after birth, indicating that fluctuating nicotine contents in 
different sessions of breastfeeding generated a postnatal nicotine withdrawal syndrome” (Friguls, 
et al., 2010). 




 Opiates are able to prevent the transmission of painful stimuli, creating an analgesic 
effect.  They are able to prevent the recognition of painful sensations while inhibiting the 
negative emotional component of pain.  They may also produce euphoria.  Opiates are divided 
into three categories based on their action mechanism: full agonist, mixed agonist-antagonist, 
and full antagonists.  There are many side effects and risks associated with the use of opiates.  
Respiratory failure is the major cause of death in intoxication cases, and addiction liability can 
cause physical dependence.  Drug tolerance is also very common, which requires an individual to 
take higher and higher concentrations of drug to produce the same effect (Kerrigan & 
Goldberger, 2010). 
Codeine. 
Codeine is a morphine agonist, in the sense that its nalgesic properties are dependent on 
its biotransformation into morphine by cytochrome P450 CYP2D6 (Friguls, et al., 2010; 
Kerrigan & Goldberger, 2010).  Approximately 10-20% of a codeine dose is excreted 
unchanged, while another 10% of the dose is metabolized to morphine.  “Further metabolism can 
produce the active metabolite morphine-6-glucuronide (M6G), which is more potent than 
morphine itself” (Kerrigan & Goldberger, 2010).  After a fatal case in which a breastfed infant 
was exposed to codeine through breast milk, both the U.S. Food and Drug Administration and 
Health Canada published warnings indicating that codeine use in breastfeeding may not be safe 
for infants (Friguls, et al., 2010; Madadi, et al.,2007).  The mother in this case was found to be 
an ultrarapid metabolizer of cytochrome P450 CYP2D6, a genetic combination that occurs at a 
frequency of one to 29% in the general population.  This caused her to quickly accumulate very 
high breast milk concentrations of morphine.  Postmr em testing of the infant revealed a blood 
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concentration of 70 ng/mL of morphine.  Milk samples were taken after the woman had cut her 
dose in half, and concentrations of 86 ng/mL were found.  It is also notable that the mother was 
homozygous for single nucleotide polymorphisms compro ising the UG 2B7*2 allele.  This 
allele is responsible for the production of M6G, which is even more potent than morphine 
(Madadi, et al., 2007).        
In a study of 17 mothers consuming codeine, milk codeine concentrations ranged from 
33.8 to 314 ng/mL from 20 to 240 minutes after codeine consumption.  The milk morphine 
concentrations ranged from 1.9 to 20.5 ng/mL during the same period of time.  Eleven of the 
infants in this study demonstrated plasma codeine lev ls of up to 4.5 ng/mL and plasma 
morphine levels up to 2.2 ng/mL.  The authors concluded that moderate use of codeine was 
probably safe (Meny, Naumburg, Alger, Brill-Miller, & Brown, 1993).  In a study of 
breastfeeding mothers receiving morphine via patient-co trolled analgesia (PCA) after cesarean 
delivery, the transfer of morphine and its active mtabolite M6G into breast milk was evaluated.  
The authors concluded that neonatal exposure did not seem to be significant (Baka, Bayoumeu, 
Boutroy, & Marie-Claire-Laxenaire, 2002).  However, another study revealed that infants 
breastfed by mothers using codeine could experience adv rse CNS effects such as drowsiness, 
apnea and cyanosis (Madadi, Shirazi, Walter, & Koren, 2008).   
 Morphine. 
Morphine is commonly prescribed to women for the management of postoperative pain 
following cesarean sections (Friguls, et al., 2010).  In a study of five lactating women who 
received morphine for postoperative pain, the M:P ratio was 2.45:1, and a peak milk 
concentration of 500 ng/mL was observed.  The authors c ncluded that the amount of morphine 
transferred to an infant was likely to be small, and was unlikely to cause any adverse effects 
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(Feilberg, Rosenborg, Christensen, & Mogensen, 1989).  In a study of a breastfeeding mother 
receiving intrathecal morphine, low levels of drug were detected in serum and milk samples.  
The breastfed infant did not demonstrate any sleep, b havior, or developmental problems 
(Oberlander, et al., 2000).  A study of a mother receiving low doses of morphine revealed a 
substantial variation in morphine milk concentrations of ten to 100 ng/mL.  Her breastfed infant 
was found to have a serum concentration of 4 ng/mL.  This value is within the analgesic range 
for infants, but as this value represents one sampling, the concentration could have been much 
higher.  No adverse effects were observed in the infant (Robieux, Koren, Vandenbergh, & 
Schneiderman, 1990). 
 Heroin. 
 Heroin (diacetylmorphine) is a synthetic morphine derivative that is one of the most 
widely abused opioids (Kerrigan & Goldberger, 2000).  Administration of the drug through 
intravenous means is the most common, followed by inhalation.  It is a highly lipid-soluble 
compound with a short half-life of 15 to 30 minutes.  Heroin is quickly hydrolyzed to 6-
monoacetylmorphine (6-MAM) by the liver, brain, heart, nd kidneys, and is then converted to 
morphine, which has a much longer half-life than heroin, at two to three hours.  There are no 
published reports of the analysis of heroin in human breast milk.  Heroin is excreted in breast 
milk in sufficient quantities to cause addiction in a  infant, and the following adverse effects 
have been reported: tremors, restlessness, vomiting, and poor feeding (Friguls, et al., 2010).  
Hydrocodone. 
 Hydrocodone is a commonly prescribed analgesic, especially in nursing mothers.  While 
clinical data is sparse, several cases of neonatal sedation have been attributed to hydrocodone use 
during breastfeeding.  Metabolism of hydrocodone to its more potent metabolite, 
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hydromorphone, occurs via the CYP2D6 enzyme.  If the nursing mother is an ultrarapid 
metabolizer of CYP2D6, higher doses of the more potnt metabolite may be passed on to the 
nursing infant (Sauberan, et al., 2011).  The M:P ratio for hydromorphone is 2.57:1, and there is 
minimal protein binding and little partitioning into he milk fat (Edwards, Rudy, Wermeling, 
Desai, & McNamara, 2003). 
In a study of two mothers who had been taking a combination of acetaminophen and 
hydrocodone, it was determined that the infants receiv d 3.1% and 3.7% of the maternal weight-
adjusted dosage.  This translated to an absolute hydrocodone dosage of 8.58 µg/kg/day and 3.07 
µg/kg/day based on the different dosages ingested by the nursing mothers.  Relative infant doses 
of less than 10% generally indicate that a medication is safe for use during breastfeeding, but 
breast milk levels of hydromorphone were not measured in this study (P. O. Anderson, Sauberan, 
Lane, & Rossi, 2007).  A pharmacokinetic study was conducted on 30 nursing mothers in an 
inpatient setting, who were receiving hydrocodone bitartrate for postpartum pain.  Their breast 
milk was analyzed for hydrocodone and hydromorphone through the use of isotope-dilution 
liquid chromatography mass spectrometry.  Fully breastf d neonates received an average of 1.6% 
(range 0.2% - 9%) of the maternal weight-adjusted hydrocodone bitartrate dosage.  When 
combined with hydromorphone, the total median opiate dosage from breast milk was 0.7% of a 
therapeutic dosage for older infants.  Most mothers excreted little to no hydromorphone into 
breast milk.  The authors concluded that standard postpartum dosages of hydrocodone appear to 
be acceptable for use in nursing mothers, but prolonged use of high dosages is not advisable 
(Sauberan, et al., 2011).  In a study of eight nursi g mothers receiving hydromorphone, it was 
determined that although the drug distributes rapidly from the plasma into breast milk, the drug 
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does not partition into fat.  It was predicted that an infant would receive approximately 0.67% of 
the maternal dose (Edwards, et al., 2003). 
Oxycodone. 
Oxycodone is an analgesic with effects similar to morphine, but with a lower incidence of 
nausea and hallucinations (Pokela, Anttila, Seppala, & Olkkola, 2005).  Due to concerns about 
neonatal CNS depression after codeine and breastfeeding, some clinicians are now prescribing 
oxycodone to nursing mothers in place of codeine (Lam, et al., 2012).  However, the prevalence 
of CNS depression as a result of oxycodone and breastfe ding does not support this view.  
Oxycodone has rapid oral absorption and high oral bioavailability.  It is a weak base with a pKa 
of 8.5, and the passage from blood to milk is favored.  It is moderately protein bound, therefore 
sufficient unbound drug would be able to pass from the maternal plasma into breast milk 
(Seaton, Reeves, & McLean, 2007).  Oxycodone is primarily metabolized by the CYP3A4 
isoenzyme to non-toxic metabolites (Hendrickson & McKeown, 2012).  Approximately 15% of 
an oxycodone dose is metabolized by CYP2D6 to oxymorphone, which is more 14 times potent 
than oxycodone (Hendrickson & McKeown, 2012; Lam, et al., 2012).  Rapid CYP2D6 
metabolizers may produce increased concentrations of the more potent oxymorphone, while poor 
CYP2D6 metabolizers may have problems clearing the par nt drug from their system 
(Hendrickson & McKeown, 2012). 
In a study of 50 breastfeeding mothers, oxycodone was detected in breast milk up to 24 
hours after dosing, regardless of the dosage amount.  The median milk-to-plasma ratio was 3.2:1.  
Over the following 48-hour period, a larger range of milk-to-plasma levels was observed.  
Oxycodone was found in breast milk up to 72 hours after dosing, and the authors concluded that 
breastfed infants may receive >10% of a therapeutic infant dose (Seaton, et al., 2007).  A study of 
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533 breastfeeding mothers and infants found that inf nts whose mothers used oxycodone while 
breastfeeding had a 20.1% rate of infant central nervous system depression (Lam, et al., 2012). 
Prevalence of Usage 
 A global review was conducted to determine the prevalence the use of 
meth/amphetamine, cannabis, cocaine, and opioids between 1990 and 2008 of people aged 15 to 
64 years.  While there was qualitative evidence of use and dependence in a large majority of the 
world’s population, there were not many estimates of the extent of such use.  Meth/amphetamine 
use or dependence was found in 181 out of 229 countries/territories of the world, which equates 
to 99% of the world’s population aged 15-64 years.  Evidence of cannabis use or dependence 
was located in 201 countries/territories, which encompasses more than 99% of the world’s 
population aged 15-64 years.  Cocaine use or dependnce was traced to 182 countries/territories 
representing more than 98% of the world’s population aged 15-64 years.  Evidence of opioid use 
or dependence was found in 192 countries/territories, which equates to more than 99% of the 
world’s population aged 15-64 years (Degenhardt, et al., 2011). 
Federal government guidelines by the Substance Abuse and Mental Health Services 
Administration (SAMHSA) require drug testing for certain employees (Substance Abuse and 
Mental Health Services Administration, 2011).  These mployees must be tested for five specific 
categories of drugs, which is referred to as the "SAMHSA 5", and was previously called the 
"NIDA-5.”  Because of this federal requirement, most drug testing companies offer a basic 
drugs-of-abuse panel that tests for drugs in these five common categories: cannabinoids 
(marijuana, hash), cocaine (cocaine, crack, benzoylec gnine), amphetamines (amphetamines, 
methamphetamines, speed), opiates (heroin, opium, codeine, morphine), and phencyclidine 
(PCP).  Many testing companies also offer an expanded panel that includes a few additional drug 
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classes and specific drugs in the testing process.  These additional categories can be added to the 
“SAMHSA 5” panel, and are typically chosen from thefollowing categories: barbiturates 
(phenobarbital, secobarbitol, butalbital), hydrocodone (Lortab, Vicodin), methaqualone 
(quaaludes), benzodiazepines (Valium, Xanax, Librium, Serax, Rohypnol), methadone, 
propoxyphene (Darvon compounds), ethanol (alcohol), and MDMA (Ecstasy) ("Drug testing 
basics," 2009).  SAMHSA recently approved the addition of additional Schedule II prescription 
medications for inclusion in the Mandatory Guidelins for Federal Drug Testing Programs.  
These Schedule II drugs include oxycodone, oxymorphone, hydrocodone, and hydromorphone 
(Hayes & Bannister, 2012). 
Each year, Quest Diagnostics releases an annual Drug Testing Index (2012).  This index 
examines the national trend of positivity rates, or the proportion of positive results for each drug 
to all such drug tests performed, among three major testing populations: federally mandated 
safety-sensitive workers, the general workforce, and the combined U.S. workforce.  Between 
January and December of 2011, Quest Diagnostics performed 1.6 million drug tests for federally 
mandated safety-sensitive workers, and 4.8 million drug tests in the general U.S. workforce.  
Due to more stringent government drug testing rules, federally mandated cutoff levels for 
cocaine and amphetamines were lowered in October of 2010.  In 2011, a 33% increase in cocaine 
positives (positivity rates increased from 0.24% to 0.32%) and a 26% increase in amphetamines 
positives (positivity rates increased from 0.35% to 0.44%) were seen in the safety-sensitive 
workforce, due in large part to the lower cutoff rules.  In the general U.S. workforce during the 
same time period, cocaine positivity increased 8% (from 0.25% to 0.27%) and amphetamine 
positivity increased 16.7% (from 0.66% to 0.77%) from the previous year.  Some of these tests 
employed the lower cutoffs required for federal testing, but an exact percentage could not be 
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determined.  Overall, amphetamine positivity has increased 75% since 2007.  Over 500,000 drug 
tests for oxycodone were administered to the general U.S. workforce in 2011, and positivity rates 
were 10% higher than in 2010 (1.0% to 1.1%), and up 25% since 2007.  Positive drug tests for 
opiates in the general workforce were up 7.7% (0.39% to 0.42%) from 2010, and up 20% since 
2007.  Positivity for propoxyphene, which was pulled off of the market in November 2010, 
decreased 84.7% from 2010.  Of all the drug tests that were non-negative (which includes invalid 
and adulterated samples), marijuana and amphetamines were seen at the highest rates, 43.3% and 
18.4% respectively, followed by opiates (9.5%), benzodiazepines (7.6%), cocaine (7.5%), 
barbiturates (3.2%), oxycodones (2.7%), and methadone (2.3%).   Propoxyphene (0.62%), PCP 
(0.54%), and MDMA (0.03%) positives were seen at much lower rates (Quest Diagnostics, 
2012). 
The U.S. Department of Health and Human Services conducts an annual survey of the 
civilian, non-institutionalized population of the United States who are 12 or older.  This survey 
interviews approximately 67,500 people each year.  The 2010 National Survey on Drug Use and 
Health (NSDUH) focused on trends between 2009 and 2010 as well as from 2002 to 2010.  The 
NSDUH obtains information on the following nine categories of illicit drugs: marijuana, cocaine, 
heroin, hallucinogens, and inhalants, as well as the nonmedical use of prescription-type pain 
relievers, tranquilizers, stimulants, and sedatives.  In 2010, an estimated 22.6 million Americans 
aged 12 or older were current illicit drug users, meaning that they had used an illicit drug during 
the month prior to the survey.  This translates to approximately 8.9% of the general population.  
Marijuana was the most commonly used illicit drug with 17.4 million past month users, or 6.9% 
of the general population.  It was used by 76.8% of current illicit drug users and was the only 
drug used by 60.1% of them.  In 2010, an estimated 15.7% (4.6 million) of past year marijuana 
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users used the drug on 300 or more days within the past 12 months, while 39.9% (6.9 million) of 
current users used the drug on 20 or more days in the past month.  An estimated 9 million people 
aged 12 or older (3.6% of the general population) were current users of illicit drugs other than 
marijuana.  The majority of these users were nonmedical users of psychotherapeutic drugs, 
including 5.1 million users of pain relievers, 2.2 million users of tranquilizers, 1.1 million users 
of stimulants, and 374,000 users of sedatives.  An estimated 1.5 million people (0.6% of the 
population) were current users of cocaine, 1.2 million people (0.5%) were users of 
hallucinogens, and 353,000 people (0.1% of the population) were users of methamphetamine.  
The NSDUH also includes a series of questions about the use of tobacco products.  An estimated 
69.6 million Americans aged 12 or older were current users of a tobacco product.  This 
represents 27.4% of the population in that age range (Substance Abuse and Mental Health 
Services Administration, 2011). 
ELISA 
An ELISA is an immunoassay test, which uses antibody interactions to identify and 
measure amounts of chemical substances.  This technique is capable of sensitivity greater than or 
equal to instrumental methods, is easy to automate, and is less subject to matrix effects than other 
analytical techniques.  ELISA kits are generally designed for a particular sample matrix.  When 
situations arise where testing is to be performed in a matrix that differs from that for which the 
kit has been validated, good science dictates that the kit be validated to demonstrate its efficacy 
in the new matrix (Hand & Baldwin, 2008; Smith, 2003). 
Drug screening. 
 In forensic toxicology, ELISA tests are used to screen biological samples for the presence 
of drugs.  To improve efficiency, pre-packaged ELISA kits are typically purchased for this 
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purpose.  The ELISA process is based on the competition between the drug or drug metabolite in 
the sample with the kit supplied drug-enzyme conjugate for a limited number of antibody 
binding sites.  Both the drug and the drug-enzyme conjugate bind to antibodies that have been 
embedded in the ELISA plate wells.  A chemical is used to develop color in the bound labeled 
drug.  Samples containing higher concentrations of drug will displace a larger amount of the 
labeled drug-enzyme conjugate than samples containig the drug at lower concentrations.  The 
proportion of bound labeled drug is inversely proportional to the amount of unlabeled drug, 
which can be determined by the extent of color development, and is captured by the absorbance 
value (Hand & Baldwin, 2008; Smith, 2003). 
Cutoffs. 
The cutoff level is a specific drug concentration at which a sample is considered to be 
positive.  A sample result is compared to the absorbance value a single-point cutoff calibrator.  
An absorbance value higher than the cutoff calibrator is declared negative, while a value lower 
than the cutoff calibrator is reported as positive.  Cutoff levels are based on the ability of the 
specific assay, the sensitivity requirements of the market for which the assay was designed, and 
what type of drug levels may be seen in the general population.  For most programs using 
immunoassays, oversight agencies mandate administrative cutoffs well above the limit of 
detection of the method.  This helps to ensure that laboratories are achieving accurate results and 
reduces the risk of identifying positive results in individuals that are passively exposed to certain 
drugs (Hand & Baldwin, 2008; Smith, 2003). 
Drug Confirmation. 
ELISA is a screening technique that is used as a presumptive test.  This means that it can 
only be used to determine if drugs of interest may be present in samples or if they are not 
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present.  Suspect samples and samples that screen positive should be confirmed using HPLC, 
LC-MS, or GC-MS (Hand & Baldwin, 2008; Smith, 2003).  In order to use these techniques, the 
drugs must be extracted from the breast milk matrix.  Due to its high protein and fat content and 
changing composition, this can be challenging (Friguls, et al., 2010).   
Methods 
Materials 
Human breast milk samples were provided by Prolacta Bioscience (Monrovia, CA).  The 
milk consisted of three samples from three different donors, and another sample of pooled milk 
from all three donors.  This milk was used for all of the optimization and validation work in this 
project, and was also used to prepare negative and cutoff calibrators for each of the ELISA 
assays.  
ELISA kits were obtained from Neogen Corporation.  Each kit contained the following 
consumables and reagents necessary to conduct the assay.  A kit-specific 96-well antibody-
coated Costar plate was provided for each assay.  Ech plate had 12 strips of eight breakaway 
wells coated with anti-drug antiserum, and was ready to use.  These breakaway strips could be 
mixed with strips from other kits so that multiple assays could be analyzed on one plate.  EIA 
buffer (phosphate buffered saline solution with bovine serum and a preservative) was provided 
for sample dilutions.  A drug-enzyme conjugate (drug-horseradish peroxidase) was provided for 
each assay.  Wash buffer concentrate (phosphate buff red saline solution with a surfactant) was 
diluted with nanopure water prior to use.  This diluted wash buffer was used to wash all the 
unbound conjugate and samples from the plate after the conjugate incubation period.  K-Blue 
substrate (stabilized 3, 3’, 5, 5’ tetramethylbenzidine plus hydrogen peroxide) was provided to 
develop color in the plate wells after the washing step.  An acid stop solution (1 N sulfuric acid) 
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was provided to stop the enzyme reaction in each instance.  Depending on the kit, serum, urine, 
and/or oral fluid calibrators were provided for each assay.  A Certificate of Analysis was 
provided for the specific lot of calibrator in each kit.  The lot # and expiration date for each kit 
component was recorded and is reported with the raw data (Attachment C through Attachment 
H).   
The following analytical drug standards were obtained from Cerilliant Corporation 
(Round Rock, TX): d-amphetamine, oxazepam, benzoylecgonine, cotinine, hydromorphone, 
morphine, d- methamphetamine, oxycodone, and ∆9-THC-COOH.  The catalog number, lot 
number, expiration date, and storage conditions for each standard are listed in Table 1.  Each 
standard was prepared in methanol at a concentration of 1 mg/mL.  Eppendorf brand pipettes and 
pipette tips were purchased for this study.  The pip ttes were calibrated prior to purchase.  The 
calibration date and lot number for each pipette are listed in Table 2.  Fisher Scientific brand 12 
x 75 mm glass tubes were utilized for sample preparation and analysis.   
A Dynex DSX Automated ELISA Four-Plate System (Chantilly, VA) was obtained from 
Neogen Corporation.  The DSX consists of a horizontal platform, which serves as the work area 
and houses sample tips (four boxes of 108 tips), reagent tips (41 tips), deep well dilution plates 
(two plates), reagent rack (holds up to 24 reagents), and the sample rack (holds up to 99 
samples).  It also contains a robotic pipette arm that travels on the x, y, and z axes for optimal 
pipetting performance, an ambient drawer that can hold up to four ELISA plates, four wash 
bottles capable of storing two liters of fluid in each bottle, a plate washer, four incubators, an 
absorbance reader, a barcode reader for plates and amples, a tip waste container, and a liquid 
waste container capable of holding eight liters. 
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The Dynex DSX was operated using Revelation software (v. 6.15).  Methods were 
written for each assay so that the DSX instrument made the necessary sample dilutions, pipetted 
all of the required samples and reagents for each assay, incubated and read each plate.  The 
disposable sample and reagent pipette tips, conjugate vi ls, calibrator vials, and deep-well 
dilution plates were also obtained from Neogen Corporation.  The instrument was installed and 
qualified prior to use by Dynex Technologies and Neogen Corporation. 
Unless otherwise specified, all of the development and validation work was performed at 
Analytical Research Laboratories (Oklahoma City, OK). 
ELISA kits 
The literature was reviewed to determine the dangers of exposing infants to breast milk 
containing drugs.  Based on this research and the prevalence of use within the general 
population, a seven-drug panel for the following categories of drugs was constructed: 
amphetamines, benzodiazepines, cocaine, nicotine, opiates, oxycodone, and cannabinoids.  
Enzyme-linked immunosorbent assays (ELISA) were used for the screening of this drug panel in 
breast milk due to their ease of use, quick turnaround time, and ability to detect low 
concentrations of drug.  ELISA kits from Neogen Corporation (Lexington, KY) were utilized for 
the seven-drug panel.  The following nine kits were initially evaluated: Amphetamine Ultra, 
Benzodiazepine Group, Cocaine/BZE, Cotinine, Hydromorphone, Methamphetamine/MDMA, 
Opiate Group, Oxycodone/Oxymorphone, and THC.  The Hydromorphone kit was not used for 
the final panel because the Opiate kit demonstrated high cross-reactivity with hydromorphone.  
The Methamphetamine/MDMA kit was not used for the final panel because the Amphetamine 
Ultra kit demonstrated high cross-reactivity with d-methamphetamine, and it was determined that 
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the identification of MDMA (3,4-methylenedioxy-N-methylamphetamine) in breast milk would 
not be pursued for this drug panel.  
The final seven-drug panel consisted of the following seven Neogen kits.  The calibrator 
for each kit was given an arbitrary value of 100%.  The response values for the additional 
analytes are ratios of the calibrator, and are expressed as percentages.  The Amphetamine Ultra 
kit used d-amphetamine as the calibrator and cross-reacted with N-desmethylselegiline at 906%, 
d-methamphetamine at 688%, and (-)- ephedrine at 49%.  The Benzodiazepine Group kit used 
oxazepam as the calibrator and cross-reacted with diazepam at 434%, estazolam at 365%, 
nordiazepam at 361%, alprazolam at 346%, tetrazepam at 264%, flurazepam at 262%, 
lormetazepam at 231%, prazepam at 198%, temazepam at 192%, halazepam at 173%, triazolam 
at 171%, 7-amino flunitrazepam at 147%, nitrazepam at 141%, N-desmethyl flunitrazepam at 
119%, flunitrazepam at 110%, bromazepam at 85%, clonazepam at 79%, lorazepam at 70%, 
midazolam at 65%, and clobazam at 59%.  The Cocaine/Be zoylecgonine kit used 
benzoylecgonine (BZE) as the calibrator, and cross-eacted with cocaine at 133%, cocaethylene 
at 124%, and m-hydroxycocaine at 96%.  The Cotinine k t used cotinine (a nicotine metabolite) 
as the calibrator and reacted with cotinine only.  The Opiate Group kit used a morphine as the 
calibrator and cross-reacted with 6-acetylcodeine at 195%, codeine at 190%, morphine-3-
glucuronide at 154%, ethylmorphine at 110%, hydrocod ne at 122%, 6-acetylmorphine at 146%, 
heroin/diacetylmorphine at 154%, nalorphine at 76%, and hydromorphone at 66%.  The 
Oxycodone/Oxymorphone kit used oxycodone as the calibrator and cross-reacted with 
oxymorphone at 88%.  The THC kit used ∆9-THC-COOH (11-nor-9-carboxy-delta-9-
tetrahydrocannabinol) as the calibrator and cross-reacted with ∆8-THC-COOH at 88%, and ∆9-
THC, the parent drug, at 4%.  This information is summarized in Table 3. 




Human breast milk samples were provided by Prolacta Bioscience (Monrovia, CA).  The 
milk consisted of three samples from three different donors, and another sample of pooled milk 
from all three donors.  Approximately ten milliliters of each sample was sent to NMS Labs 
(Willow Grove, PA) to ensure that the milk was free of drugs before it was used for project 
development and validation purposes.    
All four samples were screened for the following categories of drugs by ELISA: 
amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, 
phencyclidine, and propoxyphene.  The samples were also screened for cotinine by liquid 
chromatography – tandem mass spectrometry (LC-MS/MS).  The pooled sample was tested for 
the presence of the following categories of drugs by LC-MS/MS and gas chromatography/mass 
spectrometry (GC/MS): propoxyphene and metabolite, cocaine and metabolites, 
benzodiazepines, opiates, cannabinoids, barbiturates, phencyclidine, methadone and metabolite, 
and amphetamines. 
Method Optimization 
Sample dilutions and matrix interference. 
The effect of the human breast milk matrix on the performance of each kit was examined, 
and the ideal sample dilutions were determined according to the amount of matrix interference 
and the degree of variability between samples.  Thesmallest sample dilution that minimized 
these factors was used. 
This work was performed by Ashley Estridge at Neogen Corporation.  Five human breast 
milk samples were analyzed.  The first four samples consisted of milk received from Prolacta 
Bioscience.  These samples consisted of three samples from three different donors, and another 
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sample of pooled milk from all three donors.  The fifth sample was an in-house breast milk 
sample of traceable provenance.  These five samples were assayed with each kit, and were 
analyzed both undiluted and diluted.  Dilutions of each blank sample were examined the 
following levels: 1:2, 1:5, 1:10, 1:20, and 1:50.  EIA buffer was used to dilute the samples.  
Samples were assayed in duplicate and the assays were completed manually.  Absorbance values 
and the percent of milk matrix interference (versus EIA buffer) for each sample were compared 
for each assay.  
After the optimal dilutions were determined, the brast milk samples were pooled.  This 
pool was used to make standards at various concentratio s, as shown in Table 4.  These samples 
were assayed at the specified dilutions.  Standard curves were generated and compared to 
standard curves using standards prepared in EIA buffer, as shown in Table 5, to determine if the 
selected dilutions had a negative effect on the shape of the curve. 
Determination of cutoff levels.   
A specific cutoff level for each kit was determined based on the linear range of the 
standard curve.  Varying concentrations of breast milk and EIA buffer were prepared by spiking 
the blank matrix with the specific analytical drug standard for each kit, as depicted in Table 4 
and Table 5.  Each concentration was analyzed in duplicate.  This work was performed by 
Ashley Estridge at Neogen Corporation, and all of the assays were run manually.   
The average absorbance reading for each concentratio  was used for analysis, and 
standard curves were generated for EIA buffer and breast milk by plotting the mean B/B0 values 
against concentration on a log-logit plot.  Logit values were calculated using the following 
formula: ln[(B/B0)/(100-(B/B0))].  A regression line was calculated using the method of least 
squares, which was expressed as the coefficient of determination (r2).  The I-50, slope, and 
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intercept were also determined.  The linear range of the curve was assessed by approximating the 
70 to 30% range on each curve for the milk standards.   
Matrix interference with sample dilutions.   
The amount of milk matrix interference at the specifi d dilution for each assay was 
determined by comparing the absorbance readings between EIA buffer and human breast milk at 
the 0 ng/mL concentration, and was expressed as a percentage.   
Multi-drug calibrators.   
Multi-drug cutoff calibrators were compared to single drug cutoffs in order to determine 
if they were equivalent to one another.  The multi-drug calibrators were constructed so that 
calibrators within a group would not cross-react with any other assays.  The Group 4 and Group 
6 multi-drug calibrators were compared with single drug spikes.  The formulation and 
concentration of these standards is summarized in Table 6, and described in detail in the 
Preparation of Negative and Cutoff Calibrator section.  
Stability of calibrators in human milk.   
The stability of prepared human breast milk cutoff standards was examined over a period 
of 31 days to determine the length of time that prepa d milk standards could be used.  This work 
was performed by Ashley Estridge at Neogen Corporation, and the assays were run manually.  
The Group 4 and Group 5 multi-drug calibrators were examined at days zero, two, four, 25, and 
31.  The average absorbance value, standard deviation, nd % CV were calculated for each 
assay. 
Variability between single and multiple readings.   
Samples of negative breast milk were analyzed with each assay to determine the 
variability between absorbance readings.  Single readings of multiple wells were compared with 
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multiple readings of a single well.  Two strips of each assay were prepared as follows.  Negative 
calibrators were assayed in the first two wells, and cutoff calibrators were assayed in wells three 
and four.  A sample of negative breast milk was assayed in wells five through 14.  A single 
reading of all ten wells was taken at the completion of the run.  This same plate was then read ten 
separate times, and the reading for the ninth well of each assay was used for analysis.  The 
negative and cutoff calibrator readings were averaged for each reading.  The following 
calculations were performed on the single and multiple readings for each assay: average, 
standard deviation, percent change between the average readings and the negative calibrator, the 
%B/B0 for the calibrators, the %B/B0 for the cutoff calibrator and average reading, and the 
percent change between the two %B/B0 values. 
Validation 
Three separate validations were performed.  The first validation run used calibrators 
prepared in EIA buffer, examined nine kits (the Hydromorphone and MDMA/Methamphetamine 
kits were initially evaluated), and used morphine as the calibrator for the Opiate kit.  The results 
for the Hydromorphone and Methamphetamine/MDMA kitsare not reported, as these kits were 
not used in the finalized seven-drug panel.  This validation used Group 1, Group 2, and Group 3 
multi-drug calibrators.  The cutoff levels utilized for each validation for each kit are outlined in 
Table 6.  The ELISA plates were constructed in the following way for each validation test.  The 
first well contained the negative calibrator (blank EIA buffer), the second well contained the 
cutoff calibrator (a multi-drug calibrator spiked into EIA buffer), the third well contained the 
Neogen kit supplied negative calibrator in a serum matrix, and the fourth well contained the 
Neogen kit supplied cutoff calibrator in a serum matrix.  The Neogen calibrators were analyzed 
determine if the assays were performing correctly.  Each assay was programmed so that the 
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calibrators were taken from the control rack.  The negative and cutoff calibrators were analyzed 
one time.  Any wells analyzed following these calibrators were run as samples and were taken 
from the sample rack.  The data obtained from this run was used to further optimize the method.   
The second validation run used calibrators prepared in human breast milk.  
Hydromorphone was used as the calibrator for the Opiate kit used Group 4 and Group 5 multi-
drug calibrators.  The cutoff levels for each kit are outlined in Table 6.  The ELISA plates were 
constructed in the following manner for each validation test.  The first well contained the 
negative calibrator (blank human breast milk), the second and third wells contained the cutoff 
calibrator (a multi-drug calibrator spiked human breast milk), the fourth well contained the 
Neogen kit supplied negative calibrator in a serum matrix, and the fifth well contained the 
Neogen kit supplied cutoff calibrator in a serum matrix.  The Neogen calibrators were analyzed 
determine if the assays were performing correctly.  Each assay was programmed so that the 
calibrators were taken from the control rack.  The negative and cutoff calibrators were analyzed 
in duplicate, and the average value was determined.  Any wells analyzed following these 
calibrators were run as samples and were taken from the sample rack.  Both the calibrators and 
samples were diluted to the amount specified for each assay. 
The third validation run used calibrators prepared in human breast milk, and validated the 
final seven-drug panel.  For this validation, the negative calibrator was run in duplicate and the 
cutoff levels for the cocaine and opiate kits were increased, as shown in Table 6.  This validation 
used Group 4 and Group 6 multi-drug calibrators.  This validation was run at Prolacta Bioscience 
on a qualified Dynex DSX instrument.  The first and second wells contained the negative 
calibrator (blank human breast milk), the third and fourth wells contained the cutoff calibrator (a 
multi-drug calibrator spiked into human breast milk), the fifth well contained the Neogen kit 
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supplied negative calibrator in a serum matrix, andthe sixth well contained the Neogen kit 
supplied cutoff calibrator in a serum matrix.  The N ogen calibrators were analyzed determine if 
the assays were performing correctly.  Each assay was programmed so that the calibrators were 
taken from the control rack.  The negative and cutoff calibrators were analyzed in duplicate, and 
the average value was determined.  Any wells analyzed following these calibrators were run as 
samples and were taken from the sample rack.  Both the calibrators and samples were diluted to 
the amount specified for each assay. 
Calculation of %B/B0. 
A 50% B/B0 value was targeted for each assay.  The %B/B0 value was calculated by 
determining the ratio between the mean absorbance valu s of the cutoff and negative calibrators, 
and was expressed as a percentage.  Due to the variable nature of ELISA assays, a 30 – 70% 
range of B/B0 values for each assay was considered acceptable.  These values allow for a good 
separation of absorbance values between the negativ and cutoff concentrations.  The %B/B0 
value was calculated for each assay in each validation to determine the normal range of values.  
If a %B/B0 value was observed outside the normal range, a new calibrator was prepared.   
Preparation of negative and cutoff calibrators. 
Negative controls were prepared from human breast milk that was confirmed to be free of 
drugs.  For the initial validation, 1 mL of negative breast milk was transferred into three separate 
control vials, one for the Group 1 negative control, one for the Group 2 negative control, and one 
for the Group 3 negative control.  For the second validation, 1 mL of negative breast milk was 
transferred into two separate control vials, one for the Group 4 negative control and one for the 
Group 5 negative control.  For the third validation, 1 mL of negative breast milk was transferred 
into two separate control vials, one for the Group 4 negative control and one for the Group 6 
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negative control.  For any negative calibrators being used for sample analysis, 1 mL of the 
calibrator was transferred to a 12 x 75 mm glass tube.  All controls and samples were vortexed 
prior to analysis. 
Cutoff controls were prepared from human breast milk that was confirmed to be free of 
drugs.  The milk was vortexed prior to calibrator preparation.  For any cutoff calibrators being 
used for control purposes, 1 mL of the calibrator was transferred into a control tube.  For any 
cutoff calibrators being used for sample analysis, 1 mL of the calibrator was transferred to a 
12x75 mm glass tube.  All controls and samples were vo texed prior to analysis. 
Analytical drug standards for each assay were obtained from Cerilliant.  Each drug 
standard came prepared at a concentration of 1 mg/mL in ethanol.  A 10 µg/mL solution of 
each standard was prepared in EIA buffer using the following method.  One milliliter aliquots of 
EIA buffer were made into a glass tube for each analyte.  Using a 2-20 µL pipette, the pipette tip 
was pre-rinsed twice with EIA buffer and 10 µL was removed from the glass tube.  This was 
repeated for each analyte.  A fresh pipette tip was pre-rinsed twice with the analytical drug 
standard, 10 µL of the standard was pipetted into the glass tube of EIA buffer, and the tip was 
rinsed twice.  Any excess methanol was removed fromthe outside of the tip by wiping it on edge 
of standard stock vial.  Each tube was covered and vortexed.   
A 1 µg/mL solution was prepared with the 10 µg/mL solution using the following 
method.  Using a 100-1000 µL pipette, 250 µL of human breast milk was transferred into a 
labeled glass tube for each analyte.  Using a 20-200 µL pipette, the tip was pre-rinsed twice with 
milk and 25 µL was removed from the glass tube.  This was repeated for each analyte.  Using a 
20-200 µL pipette, a fresh pipette tip was pre-rinsed twice with the 10 µg/mL solution and 25 µL 
of this solution was transferred into the glass tube of milk corresponding to that analyte.  This 
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was repeated for each analyte.  The tubes containing the 1 µg/mL solution were covered and 
vortexed.  This solution was used to prepare the multi-drug calibrators and the accuracy samples. 
Preparation volumes for the solutions and cutoff calibr tors were scaled up depending on 
the needs of the particular validation run.  The process for the preparation of the Group 4 and 
Group 6 cutoff controls are detailed below.  The concentrations for the cutoff controls from 
Group 4, Group 2, Group 3, and Group 5 are summarized in Table 6.  The Group 4 and Group 6 
cutoff calibrators were prepared using the 1 µg/mL solution.  The Group 4 cutoff calibrator 
contained d-amphetamine, cotinine, and oxycodone for use with the Amphetamine Ultra, 
Cotinine, and Oxycodone/Oxymorphone assays.  To prepare the Group 1 cutoff calibrator, 1 mL 
of human breast milk was transferred into a glass tube.  Using a 20-200 µL pipette, the tip was 
pre-rinsed twice with milk and 130 µL was removed from the glass tube.  Using a 20-200 µL 
pipette, a fresh pipette tip was pre-rinsed twice with the 1 µg/mL solution for d-Amphetamine 
and 50 µL of the this solution was pipetted into the glass tube of milk.  This procedure was 
repeated for the cotinine and oxycodone solutions, with 50 µL of cotinine and 30 µL of 
oxycodone being added to the tube of human milk.  The tube was covered and vortexed.   
The Group 6 cutoff calibrator contained oxazepam, benzoylecgonine, hydromorphone, 
and ∆9-THC-COOH for use with the Benzodiazepine Group, Cocaine/BZE, Opiate Group, and 
THC assays.  To prepare the Group 6 cutoff calibrator, 1 mL of human breast milk was 
transferred into a glass tube.  Using a 20-200 µL pipette, the tip was pre-rinsed twice with milk 
and 170 µL of milk was removed from the glass tube.  Using a 20-200 µL pipette, a fresh pipette 
tip was pre-rinsed twice with the 1 µg/mL solution f r oxazepam and 50 µL of the this solution 
was pipetted into the glass tube of milk.  This procedure was repeated for the benzoylecgonine, 
hydromorphone, and ∆9-THC-COOH solutions, with 50 µL of benzoylecgonine, 50 µL 
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hydromorphone, and 20 µL of ∆9-THC-COOH being added to the tube of human milk.  The tube 
was covered and vortexed. 
Test procedures. 
The following test procedures were written into thepr -defined assays.  A minimum 
volume of 50 µL for each breast milk calibrator and sample was transferred to a deep-well plate 
and was diluted with EIA buffer to the appropriate dilution value for each assay.  Mixing in the 
deep well plate occurred immediately after the calibr tor or sample was dispensed, and three mix 
cycles were performed.  For the Amphetamine Ultra, Benzodiazepine Group, 
Oxycodone/Oxymorphone, and THC assays, 10 µL of each c librator and sample were 
transferred to the appropriate microtiter wells.  For the Cocaine/BZE, Cotinine, and Opiate 
Group assays, 20 µL of each calibrator and sample wer transferred to the appropriate microtiter 
wells.  For the Amphetamine Ultra, Benzodiazepine Group, Cotinine, Oxycodone/Oxymorphone, 
and THC assays, 100 µL of each assay conjugate were transferred to the appropriate microtiter 
wells.  For the Cocaine/BZE and Opiate Group assays, 180 µL of each assay conjugate were 
transferred to the appropriate microtiter wells.  All of the assays, with the exception of Cotinine, 
incubated for 45 minutes at ambient temperature.  The Cotinine microtiter plates incubated for 
30 minutes at room temperature.  After the conjugate incubation period, the liquid was aspirated 
from each well and each plate was washed five times.  For each wash cycle, 300 µL of wash 
buffer was dispensed to each well, and then was aspirated.  After the final cycle, the washer 
performed an additional aspiration step, and the washer was cleaned with 3 mL of deionized 
water.  Each well was then filled with 100 µL of K-Blue Substrate (150 µL for the Cotinine 
assay).  All assays, with the exception of Cotinine, cubated for 30 minutes an ambient 
temperature.  The Cotinine assay incubated for 15 minutes at ambient temperature.  After the 
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substrate incubation period, 100 µL of Acid Stop (150 µL for the Cotinine assay) was added to 
each well to halt the enzyme reaction.  The absorbance of each plate was read at 450 nm.  
Drift.   
Negative and cutoff calibrators were assayed in the first and last wells of the run to 
ensure that the controls performed similarly at the beginning and end of the plate.  Three strips of 
eight wells were set up for each assay.  The calibrators were run in the first four wells for the 
first validation, in the first five wells for the second validation, and in the first six wells for the 
final validation.  A negative calibrator was run as a ample in well 23, and a cutoff calibrator was 
run as a sample in well 24.  Samples of blank EIA buffer were analyzed in the remaining wells. 
The %B/B0 for each calibrator set was calculated.  If any of the calibrators in the first 
wells were run in duplicate, the average was used for analysis.  While many ELISA validations 
set their cutoff for plate drift at 20 or 25% CV (DeSilva, et al., 2003; Findlay, et al., 2000; Kelley 
& DeSilva, 2007; Schwope, et al., 2010), the U.S. Food and Drug Administration (FDA) specify 
that precision determinations should not exceed 15%CV (U.S. Department of Health and 
Human Services, FDA, CDER, 2001).  For this study, the 15% CV guideline for precision was 
also applied to the plate drift determination.  The drift validation passed if there was less than 
15% variation between the %B/B0 for the first and last set of calibrators.   
Precision.   
Negative and cutoff controls were assayed in every other sample well to confirm the 
precision of the instrument and the performance of the calibrators.  “The precision of an 
analytical method describes the closeness of individual measures of an analyte when the 
procedure is applied repeatedly to multiple aliquots of a single homogenous volume of biological 
matrix” (USDHHS, FDA, CDER, 2001).  Precision was run two separate times for each 
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validation run, for a total of six precision assays.  A larger volume of milk was prepared for both 
the negative and cutoff samples.  Aliquots were takn from each single homogenous volume for 
precision analysis.  Three strips of eight wells were set up for each assay.  The calibrators were 
run in the first four wells for the first validation, in the first five wells for the second validation, 
and in the first six wells for the final validation.  Samples of negative and cutoff calibrators were 
alternated in the remaining wells.   
The standard deviation and % CV was calculated separately for the negative samples and 
the cutoff samples in each run.  According the FDA, the precision determinations for each 
concentration level should not exceed 15% CV (USDHHS, FDA, CDER, 2001).  The precision 
validation passed if there was less than 15% CV for the negative samples and cutoff samples in 
each run.  
Accuracy.   
The accuracy validation assessed the ability of each assay to correctly determine the true 
result.  Analytical drug standards were spiked intobreast milk at 50% below the cutoff level, at 
the cutoff level, and 50% above of the cutoff level.  The preparation for these spikes is detailed 
in Table 7 and Table 8.  For the first and second validation, nine replicates of each level were 
analyzed.  For the third validations, six replicates of each level were analyzed.  The absorbance 
value of each sample was compared to the absorbance v lue of the cutoff control in order to 
make a positive or negative determination.  If the absorbance value of the sample was greater 
than the absorbance of the cutoff calibrator, the sample was negative.  If the absorbance value of 
the sample was less than the absorbance of the cutoff alibrator, the sample was positive.   The 
accuracy validation passed if there were no false positives for the samples at 50% below the 
cutoff level and no false negatives for the samples at 50% above the cutoff level. 
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Sample analysis.   
Nineteen samples of human breast milk were screened at Prolacta Bioscience using the 
finalized ELISA seven-drug panel.  These samples originated from nineteen different donors, 
and were de-identified prior to screening.  The samples had screened negative for the presence of 
opiates/morphine, marijuana, cocaine/BZE, benzodiazepines, methamphetamine, and 
amphetamine by personnel at Prolacta through the use of an immunochromatographic assay.   
Data Analysis 
 All data was analyzed using a current statistical analysis computer program (Excel for 
Windows, version 14.0, Redmond, WA). 
Results and Discussion 
Screening 
Human breast milk samples were provided by Prolacta Bioscience (Monrovia, CA).  The 
milk consisted of three samples from three different donors, and another sample of pooled milk 
from all three donors.  All four samples were screened for the following categories of drugs by 
ELISA: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, 
opiates, phencyclidine, and propoxyphene.  The samples were also screened for cotinine by LC-
MS/MS.  The screening results for all four samples w re negative.  The pooled sample was then 
confirmed to be negative for the presence of the following categories of drugs by LC-MS/MS 
and GC/MS: propoxyphene and metabolite, cocaine and metabolites, benzodiazepines, opiates, 
cannabinoids, barbiturates, phencyclidine, methadone and metabolite, and amphetamines.  The 
methods and cutoff levels for each test are listed in Attachment A.  The results are detailed in the 
NMS Labs issued Toxicology Report (Attachment B).   
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It is imperative that any breast milk that will be used for preparation of calibrators or 
assay validation is verified as being truly negative for the presence of drugs.  If any drugs are 
present in the milk, and this milk is used as a negative calibrator or is fortified with analytical 
drug standards and used as a cutoff calibrator, the resultant values will not be a true 
representation of the level for a negative or cutoff.  Any results obtained using these calibrators 
are likely to be inaccurate. 
Method Optimization 
Sample dilutions and matrix interference. 
Absorbance values of sample dilutions versus EIA buffer were compared, and the amount 
of matrix interference was calculated.  The undiluted milk samples showed interference in all of 
the assays.  This was demonstrated by a reduction in the absorbance of the milk sample when 
compared to the absorbance of EIA buffer.  The Cotinine assay showed the least amount of 
matrix interference at 20.3%, while the THC assay demonstrated the greatest amount of matrix 
interference at 73.6%.  The degree of variability between samples was lowest in the 
Benzodiazepine Group, Cocaine/BZE, Cotinine, Opiate Group, and Oxycodone/Oxmorphone 
assays, greater in the Amphetamine Ultra assay, and greatest in the THC assay.  Dilutions of the 
milk samples reduced the amount of matrix interference and lessened the degree of variability 
between samples while producing absorbance values that more closely approximated the values 
of EIA buffer.  This data is summarized in Table 9.  The optimal dilutions were determined by 
selecting the smallest dilution that minimized both the matrix effect of the milk along with the 
degree of variability between samples.  These dilutions are depicted in Table 10.  Due to a high 
degree of matrix interference and variability between samples, samples were diluted 1:100 in 
EIA buffer for the THC kit only.   
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After the optimal dilutions were determined, the brast milk samples were pooled.  This 
pool was used to make standards at various concentratio s, as shown in Table 11 through Table 
16.  After these samples were assayed at the specified d lutions, standard curves were generated 
and compared to standard curves using standards prepared in EIA buffer (Figure 1 through 
Figure 7).  The selected sample dilutions did not appe r to have any negative effects on the shape 
of the standard curves for breast milk.  
Determination of cutoff levels.   
The initial cutoff levels were based on the linear range along with the levels of the serum 
calibrators included with each kit.  For the Amphetamine Ultra, Benzodiazepine Group, 
Cocaine/BZE, Cotinine, Opiate Group, the serum calibr tors were at a concentration of 50 
ng/mL.  The Oxycodone/Oxymorphone calibrator was at 10 ng/mL and the THC calibrator was 
at 5 ng/mL.   
The 70-30% B/B0 range for each assay was approximated.  The widest ranges of cutoff 
values were seen in the Amphetamine Ultra and Cotinine assays, while the narrowest ranges 
were seen in the Oxycodone/Oxymorphone, Cocaine/BZE, and THC assays.  The linearity data, 
including the approximate linear range for each kit are listed in Table 11 through Table 16.  The 
following cutoffs were proposed: Amphetamine Ultra – 50 ng/mL, Benzodiazepine Group – 50 
ng/mL, Cocaine/BZE – 30 ng/mL, Cotinine – 50 ng/mL, Opiate Group – 30 ng/mL, 
Oxymorphone/Oxycodone – 30 ng/mL, and THC – 20 ng/mL.  The proposed cutoff levels 
remained unchanged with the exception of the Cocaine/BZE and Opiate Group assays.  Both 
assays were initially set at 30 ng/mL, but were raised to 50 ng/mL because of false negative 
results being obtained during the accuracy validation.   
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As there is very little research on the range of drug concentrations seen in human breast 
milk and the concentrations that could be harmful to infants, these cutoff levels may need to be 
scaled up or down within the linear range.  As more research is done in this area on larger 
populations of breastfeeding women, the prevalence of oncentrations can be determined.  
Further research is needed to ascertain drug concentratio s that may cause harm to infants.  
Matrix interference with sample dilutions.   
The amount of milk matrix interference at the specifi d dilution for each assay was 
determined by comparing the absorbance readings between EIA buffer and human breast milk at 
the 0 ng/mL concentration, and was expressed as a percentage.  The interference varied from a 
low of 1% in the Oxycodone/Oxymorphone assay, to 20% for the Opiate Group assay.  Despite 
the 20% matrix interference, the Opiate Group assay performed well in the validations, with the 
exception of accuracy.  This issue was resolved by increasing the cutoff level, but it is possible 
that the sample dilution could be increased while maintaining the lower cutoff level.  The THC 
assay, which demonstrated 73.6% interference with undil ted breast milk, was reduced to 3% 
matrix interference when a 1:100 dilution was utilized.  The absorbance values and percent 
matrix interference are listed in Table 18. 
Multi-drug calibrators. 
The multi-drug calibrators demonstrated similar performance to the single drug 
calibrators.  The percent difference between the multi-drug and single drug calibrators was under 
6% for the majority of the assays.  There was a 10.7% difference between calibrators for the 
Cocaine/BZE assay, and a 14.6% difference between calibrators for the Benzodiazepine Group 
assay. The data suggests that less drug was spiked in the multi-drug calibrators than in the single 
drug calibrators, which could be attributed to human error.  The %B/B0 values of these two 
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assays still fall within the range of %B/B0 values observed in the second and third validations 
(Table 19).  The data for the comparison of multi-drug and single drug calibrators is depicted in 
Attachment C, and is summarized in Table 20.  
The use of multi-drug calibrators streamlines the amount of controls that need to be 
prepared and reduces the amount of reagents and consumables needed when analyzing samples.  
For the purposes of high-throughput sample analysis, the use of multi-drug calibrators is 
recommended.  
Stability of calibrators in human milk. 
Drugs at the cutoff concentrations were found to be stable in human milk for at least 31 
days when stored at refrigerated conditions (2-8 ºC).  The % CV for the five time points ranged 
from 5% for the Benzodiazepine Group and THC assays to 15% for the Cocaine/BZE assays.  
Aside from the Cotinine assay, there was not a demonstration of linear degradation for any of the 
assays.  The data is summarized in Table 21.   
For quality control purposes, the majority of human milk banks store unpasteurized 
human milk at -20 to -30°C for up to three months (Wojcik, et al., 2009).  The Academy of 
Breastfeeding Medicine (2004) recommends that human ilk be stored at refrigerated conditions 
(approximately 4°C) for no longer than five days, and t frozen conditions (approximately -
20°C) for no longer than 12 months.  Milk stored for longer periods is still safe for consumption, 
but research has shown that lipids start to degrade, esulting in a lower quality product (The 
Academy of Breastfeeding Medicine, 2004).  As the calibrators have demonstrated stability for 
31 days, it is recommended that new calibrators be prepared every five days when stored at 
refrigerated conditions.  
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Variability between single and multiple readings. 
The single reading of ten multiple wells provided more robust data than multiple readings 
of a single well.  The absorbance readings continued to fall as each reading was made, and this is 
likely due to the amount of time that elapsed betwen ach of the readings.  The acid stop 
applied to the wells makes the wells stable to readfor a certain period of time, but the stability 
drops off as the acid stop continues to react within e well.  The data is depicted in Attachment 
D, and is summarized in Table 22 and 23. 
For the single readings of multiple wells, the percent change between the average 
absorbance of the multiple readings and the negative calibrator ranged from a low of 1.2% in the 
Oxycodone/Oxymorphone assay and 6.5% in the Amphetamine Ultra assay to a high of 17.5% in 
the Cocaine/BZE assay and 30.5% in the Cotinine assay.  For the multiple readings of a single 
well, the percent change between the average absorbance of the multiple readings and the 
negative calibrator ranged from a low of 0.2% in the Oxycodone/Oxymorphone assay and 2.0% 
in the Amphetamine Ultra assay to a high of 22.4% in the Cocaine/BZE assay and 45.4% in the 
Cotinine assay.  The trends were identical between single and multiple readings for all assays.  
This shows that the variability for the Cocaine/BZE and Cotinine assays is likely to be greater 
than the variability seen in the other assays.  This variability did not have any effect on the 
qualitative results obtained from the final validaton.  The majority of the %B/B0 values did not 
fall within the range of values seen in the second a  third validations.  Again, these values did 
not have a negative effect on the ability of the assay  to obtain qualitative results and may be 
attributed to the day-to-day variability that occurs in ELISA assays. 
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Validation   
Drift. 
The % CV was consistently lower when the calibrators were prepared in breast milk 
versus EIA buffer, with the exception of the Benzodiazepine Group and Opiate Group assays.  
When the Cocaine/BZE, Oxycodone/Oxymorphone, and Opiate Group assays were run during 
the second validation, the % CV for the Cocaine/BZE assay was 20.78%, the % CV for the 
Oxycodone/Oxymorphone assay was 17.76%, and the average %B/B0 for the Opiate Group 
assay was 86.72%, which was much higher than expected.  New calibrators were prepared, and 
these assays were repeated.  The Cocaine/BZE % CV dropped to 1.15%, and the Oxycodone % 
CV dropped to 1.72%.  The Opiate Group average %B/B0 dropped to 72.94%, while the % CV 
rose from 2.04 to 10.24.  During the final validation, the THC assay had a low % CV of 1.10%, 
but the average %B/B0 was extremely high at 91.09%.  New calibrators were prepared and 
analyzed with the calibrators producing the high B/B0 values.  Drift was not evaluated, but the 
%B/B0 dropped to 72.55% and the original calibrator had an absorbance value of 1.055 while the 
new calibrator had an absorbance value of 1.069.  The absorbance values for the cutoff calibrator 
obtained during the drift run were most likely the result of some type of error.  It is important to 
track the typical range of %B/B0 values so that errant results can be detected. 
The cutoff levels for the Cocaine/BZE and Opiate Group assays were raised from 30 
ng/mL for the second validation to 50 ng/mL for thefinal validation.  The average %B/B0 values 
for the Cocaine/BZE dropped from 80.78% to 61.02% and from 86.73% and 78.01% to 57.33% 
for the Opiate assay.  
All of the drift validations passed as there was less than 15% variation between the 
%B/B0 for the beginning control set and the ending control set for each assay.  The data for each 
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validation is depicted in Attachment E through Attachment G, and the results of each drift 
validation are summarized in Table 24. 
Precision. 
The % CV for the negative and cutoff calibrators for the first and second run of each day 
was similar.  The second validation run demonstrated more variability in the % CV for the cutoff 
calibrators between the first and second run of each d y.  Outliers were removed from data 
obtained during the first two runs of the first valid tion and from the second run of the second 
validation.  The values removed from the first valid t on were consistently in the same wells 
between assays.  As this data was not being used to validate the final panel, the values were 
removed without performing statistical analyses.  A Grubb’s test for outliers was performed on 
the precision data from the second validation in order to demonstrate that the data point was 
indeed an outlier.  The Benzodiazepine Group, Cocaine/BZE, Opiate Group, and THC assays all 
had outlying data within the same well position for each assay, and were all prepared as the 
Group 5 calibrator.  The Grubbs value for each assay was calculated using the following 
formula: G = (ymax-ymin)/SD.  The Benzodiazepine Group assay had a Grubbs value of 3.12, the 
Cocaine/BZE assay had a Grubbs value of 3.44, the Opiate Group assay had a Grubbs value of 
3.50, and the THC assay had a Grubbs value of 3.30. Based on the sample size of nine values, 
the critical Z value for an upper one-tailed test was 2.323 at a significance level of 0.01.  Because 
the G values were all greater than the critical Z value, the maximum values in each data set were 
outliers.  The following values were removed from each assay: 2.435 - Benzodiazepine Group, 
1.453 – Cocaine/BZE, 1.787 – Opiate Group, 1.898 – THC.  The resultant average, standard 
deviation, and % CV for each assay is reported in Table 25.  The corresponding data for each 
validation is depicted in Attachment E through Attachment G.  
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All three precision validations passed because the % CV for the negative and cutoff 
calibrators was less than 15%.  This confirms the precision of the instrument and the 
performance of the calibrators.   
Accuracy. 
When samples are prepared at the cutoff level, they ma  return either a positive or 
negative result, as the sample concentration is so close to the concentration of the cutoff 
calibrator.  Ideally, sample prepared exactly at the cutoff should come back negative.  The 
accuracy of each assay improved when calibrators prepared in breast milk were utilized.  The 
only problem assays for the second validation were Cocaine/BZE and Opiate Group with false 
positives and Oxycodone/Oxymorphone with false negatives.  The Cocaine/BZE and Opiate 
group assays were remedied by increasing the cutoff levels from 30 ng/mL to 50 ng/mL.  Both of 
these assays passed at 100% in the final validation.  The false negative for the 
Oxycodone/Oxymorphone assay was determined to be anoutlier using the Grubbs test.  The 
problem well had an absorbance value of 1.667, which was higher than the average for both the 
cutoff level and 50% above the cutoff level.  This well had a G value of 3.34, making it an 
outlier for an upper one-tailed test at a significance level of 0.01.  When this assay was analyzed 
during the final validation, it passed with 100% accuracy.  Only the final accuracy validation 
passed, as all of the samples prepared at 50% above nd 50% below the cutoff level were 
correctly identified.  The data for each validation s depicted in Attachment E through 
Attachment G, and the accuracy results are summarized in Table 26. 
The failing assays from the second validation were r peated after the final validation 
using the revised cutoff levels, and passed with 100% accuracy.  The results are not reported, but 
this demonstrates the robustness of the method between two different sites. 
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Sample analysis.   
All nineteen milk samples screened negative using the finalized ELISA seven-drug panel, 
and the data is depicted in Attachment H.  This supports the negative results obtained with the 
immunochromatographic screen.  There were no matrix issues seen with milk from a variety of 
different donors. 
Conclusions 
A seven-drug panel was successfully optimized and vali ated for the screening of licit 
and illicit drugs in human breast milk.  This method is robust and was successfully validated at 
two different sites.  The details of the final seven-drug panel are detailed in Table 27. 
Future Research 
 It is suggested that the sensitivity and specificity of this method be explored by 
examining blinded samples of breast milk prepared at 50% above and below the cutoff level for 
each assay.  By examining multiple samples instead of replicates of one sample, the diagnostic 
sensitivity and specificity can be determined (Schwope, et al., 2010). 
 A limited number of breast milk donors were examined in this study.  Although there 
were not any issues with assay performance between th se donors, additional research should be 
undertaken.  The composition of breast milk changes ov r time and is likely to be different 
between individuals (Wojcik, et al., 2009), so further study is needed to determine if these 
changes affect the ability of the ELISA assays to detect drugs. 
For this study, human breast milk samples were not available from women who were 
known users of the drugs tested in this panel.  Because all individuals metabolize drugs 
differently, the concentrations of drugs and metabolites in breast milk may differ from person to 
person.  Samples of milk obtained from women who have been taking drugs should be screened 
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by this ELISA panel to determine if there is a difference between metabolized samples and drug 
spiked samples. 
 Due to the complicated metabolism associated with the transition of drugs from plasma 
into breast milk, it is difficult to determine the range of drug concentrations that may be present 
in the general population of breastfeeding women.  This is a difficult subject to study, due to the 
dangers and ethical dilemmas that are intrinsic in examining the relationship of drug use, 
breastfeeding, and the possible dangers to infants.  As there is no therapeutic infant dose for 
many of the drugs in this panel, it is difficult to say what breast milk levels may be harmful.  The 
cutoff levels suggested in this study may need to be scaled up or down depending on what is 
found in future research. 
 The composition of breast milk may have an effect on what concentrations are seen in 
samples.  For example, if drugs tend to partition into milk with a higher preponderance of fat, it 
may be more difficult to detect the drug’s presence i  samples that are lower in fat content.  
Additional research could be done to determine the ability of drugs to pass into samples of 
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NUMBER EXP. DATE 
STORAGE 
CONDITIONS 
S(+)-Amphetamine                     
(dextro-Amphetamine) 
A-008 FE042511-01 4/2016 Refrigerator 
Oxazepam O-902 FE111710-02 11/2014 Freezer 
Benzoylecgonine B-004 FE012411-02 2/2016 Freezer 
(-)-Cotinine C-016 FN051110-04 5/2015 Freezer 
Hydromorphone H-004 FE020410-01 2/2015 Freezer 
Oxycodone O-002 FE092910-02 9/2015 Refrigerator 
Morphine M-005 FE080411-01 8/2016 Freezer 
(±)-Methamphetamine M-009 FE061710-02 6/2015 Refrigrator 


































Eppendorf® Research® Plus pipette, 
adjustable volume 
 2-20 µL 496487Z 9/27/2012 
Eppendorf® Research® Plus pipette, 
adjustable volume 
20-200 µL 284487A 9/27/2012 
Eppendorf® Research® Plus pipette, 
adjustable volume 




































Neogen Corporation Kits, Calibrators, and Cross-Reactivity 











d-Amphetamine (100%)  









































Cotinine Cotinine Cotinine (100%) 
Opiate Group Hydromorphone 
 
Morphine (100%)  
6-acetylcodeine (195%)  
Codeine (190%)  
Morphine-3-glucuronide 
(154%) 
Ethylmorphine (110%)  
 








Oxycodone Oxycodone (100%)  Oxymorphone (88%) 
THC ∆9-THC-COOH ∆9-THC-COOH (100%)  ∆8-THC-COOH (88%) 










Standard Formulations for Linearity Analysis in Human Breast Milk 
STOCKS CONCENTRATION 
VOLUME OF DILUTION 
INTO 5mL BREAST MILK 
STOCK 1 mg/mL  
A 1 µg/mL 5 µL STOCK 
B 1 ng/mL 5 µL A 





VOLUME OF DILUTION 
INTO 2mL BREAST MILK 
0.25 B/5 400 µL B 
0.5 B/2 1000 µL B 
2 A/500 4 µL A 
2.5 A/400 5 µL A 
4 A/250 8 µL A 
5 A/200 10 µL A 
10 A/100 20 µL A 
16 A/62.5 32 µL A 
20 A/50 40 µL A 
25 A/40 50 µL A 
30 A/33.33 60 µL A 
40 A/25 80 µL A 
50 A/200 100 µL A 
100 A/100 200 µL A 
200 A/5 400 µL A 
250 A/4 500 µL A 
500 A/2 1000 µL A 
1000 A A 
5000 STOCK/200 10 µL STOCK 
 
 




Standard Formulations for Linearity Analysis in EIA Buffer 
STOCKS CONCENTRATION 
VOLUME OF DILUTION 
INTO 5mL EIA BUFFER 
STOCK 1 mg/mL  
A 1 µg/mL 5 µL STOCK 
B 1 ng/mL 5 µL A 





VOLUME OF DILUTION 
INTO 2mL EIA BUFFER 
0.05 B/20 100 µL B 
0.1 B/10 200 µL B 
0.2 B/5 400 µL B 
0.3 B/3.33 600 µL B 
0.5 B/2.5 800 µL B 
0.8 B/1.25 1600 µL B 
1 B B 
2 A/500 4 µL A 
5 A/200 10 µL A 
10 A/100 20 µL A 
20 A/50 40 µL A 
50 A/200 100 µL A 
100 A/100 200 µL A 
500 A/2 1000 µL A 













Formulation of Multi-Drug Calibrators. 
Group 1 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Amphetamine Ultra d-Amphetamine 50 ng/mL 
Cocaine/BZE Benzoylecgonine 30 ng/mL 
Hydromorphone Hydromorphone 0.25 ng/mL 
 
Group 2 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Methamphetamine/MDMA d-Methamphetamine 50 ng/mL 
Oxycodone/Oxymorphone Oxycodone 30 ng/mL 
THC ∆9-THC-COOH 20 ng/mL 
   
Group 3 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Benzodiazepine Group Oxazepam 50 ng/mL 
Cotinine Cotinine 50 ng/mL 
Opiate Group Morphine 30 ng/mL 
   
Group 4 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Amphetamine Ultra d-Amphetamine 50 ng/mL 
Cotinine Cotinine 50 ng/mL 
Oxycodone/Oxymorphone Oxycodone 30 ng/mL 
 
Group 5 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Benzodiazepine Group Oxazepam 50 ng/mL 
Cocaine/BZE Benzoylecgonine 30 ng/mL 
Opiate Group Hydromorphone 30 ng/mL 
THC ∆9-THC-COOH 20 ng/mL 
   
Group 6 Cutoff Calibrator 
Assay Calibrator Cutoff Level (ng/mL) 
Benzodiazepine Group Oxazepam 50 ng/mL 
Cocaine/BZE Benzoylecgonine 50 ng/mL 
Opiate Group Hydromorphone 50 ng/mL 
THC ∆9-THC-COOH 20 ng/mL 














VOLUME OF 1 µg/mL 
SOLUTION INTO 
1000µL EIA BUFFER 
Amphetamine Ultra d-Amphetamine 25 25µL 
Benzodiazepine Group Oxazepam 25 25µL 
Cocaine/BZE BZE 15 15µL 
Cotinine Cotinine 25 25µL 
Opiate Group Morphine 15 15µL 
Oxycodone/Oxymorphone Oxycodone 15 15µL 
THC ∆9-THC-COOH 10 10µL 





VOLUME OF 1 µg/mL 
SOLUTION INTO 
1000µL EIA BUFFER 
Amphetamine Ultra d-Amphetamine 50 50µL 
Benzodiazepine Group Oxazepam 50 50µL 
Cocaine/BZE BZE 30 30µL 
Cotinine Cotinine 50 50µL 
Opiate Group Morphine 30 30µL 
Oxycodone/Oxymorphone Oxycodone 30 30µL 
THC ∆9-THC-COOH 20 20µL 





VOLUME OF 1 µg/mL 
SOLUTION INTO 
1000µL EIA BUFFER 
Amphetamine Ultra d-Amphetamine 75 75µL 
Benzodiazepine Group Oxazepam 75 75µL 
Cocaine/BZE BZE 45 45µL 
Cotinine Cotinine 75 75µL 
Opiate Group Morphine 45 45µL 
Oxycodone/Oxymorphone Oxycodone 45 45µL 




















Amphetamine Ultra d-Amphetamine 25 25µL 
Benzodiazepine Group Oxazepam 25 25µL 
Cocaine/BZE BZE 25 25µL 
Cotinine Cotinine 25 25µL 
Opiate Group Morphine 25 25µL 
Oxycodone/Oxymorphone Oxycodone 15 15µL 
THC ∆9-THC-COOH 10 10µL 









Amphetamine Ultra d-Amphetamine 50 50µL 
Benzodiazepine Group Oxazepam 50 50µL 
Cocaine/BZE BZE 50 50µL 
Cotinine Cotinine 50 50µL 
Opiate Group Morphine 50 50µL 
Oxycodone/Oxymorphone Oxycodone 30 30µL 
THC ∆9-THC-COOH 20 20µL 









Amphetamine Ultra d-Amphetamine 75 75µL 
Benzodiazepine Group Oxazepam 75 75µL 
Cocaine/BZE BZE 75 75µL 
Cotinine Cotinine 75 75µL 
Opiate Group Morphine 75 75µL 
Oxycodone/Oxymorphone Oxycodone 45 45µL 











Comparison of Sample Dilutions on Matrix Interferenc  for Each Assay 
  DILUTION EIA 
Buffer   Neat 1:2 1:5 1:10 1:20 1:50 











Prolacta Sample #1 1.033 1.023 1.238 1.451 1.472 1.557   
Prolacta Sample #2 1.971 1.676 1.592 1.529 1.425 1.541   
Prolacta Sample #3 0.994 1.019 2.360 1.962 1.735 1.767   
Prolacta Sample #4 0.943 1.024 1.200 1.333 1.666 1.760   
In-House Sample #1 1.054 1.298 1.410 1.409 1.469 1.550   
Average 1.199 1.208 1.560 1.537 1.553 1.635 1.841 
Standard Deviation 0.416 0.288 0.473 0.248 0.170 0.160   
% CV 34.7% 23.9% 30.3% 16.1% 10.9% 9.8%   












 Prolacta Sample #1 0.800 0.910 1.040 1.146 1.287 1.461   
Prolacta Sample #2 1.004 1.024 1.197 1.250 1.358 1.515   
Prolacta Sample #3 0.933 1.023 1.244 1.310 1.422 1.489   
Prolacta Sample #4 0.915 1.023 1.159 1.257 1.427 1.522   
In-House Sample #1 1.061 1.212 1.287 1.403 1.491 1.552   
Average 0.942 1.038 1.185 1.273 1.397 1.507 1.710 
Standard Deviation 0.095 0.109 0.097 0.091 0.077 0.044   
% CV 10.1% 10.5% 8.2% 7.2% 5.5% 2.9%   









Prolacta Sample #1 0.849 1.131 1.332 1.427 1.467 1.567   
Prolacta Sample #2 0.875 1.209 1.353 1.453 1.491 1.525   
Prolacta Sample #3 0.810 1.026 1.111 1.446 1.448 1.548   
Prolacta Sample #4 0.835 1.090 1.312 1.413 1.464 1.510   
In-House Sample #1 0.910 1.215 1.434 1.430 1.486 1.562   
Average 0.856 1.134 1.308 1.434 1.471 1.542 1.632 
Standard Deviation 0.046 0.078 0.116 0.028 0.024 0.031   
% CV 5.3% 6.8% 8.9% 2.0% 1.7% 2.0%   






Prolacta Sample #1 1.935 2.192 2.771 2.390 2.258 2.171   
Prolacta Sample #2 1.736 1.684 1.931 2.087 2.711 2.792   
Prolacta Sample #3 1.973 2.207 1.760 1.843 1.919 2.089   
Prolacta Sample #4 1.605 1.820 1.796 1.985 1.741 1.741   
In-House Sample #1 1.761 1.792 1.841 1.851 1.883 2.008   
Average 1.802 1.939 2.019 2.031 2.102 2.160 2.290 
Standard Deviation 0.160 0.266 0.407 0.233 0.378 0.378   
% CV 8.9% 13.7% 20.1% 11.4% 18.0% 17.5%   
Matrix Interference 21.3% 15.3% 11.8% 11.3% 8.2% 5.7%   
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Table 9, continued 
  DILUTION EIA 
Buffer   Neat 1:2 1:5 1:10 1:20 1:50 









Prolacta Sample #1 1.061 1.289 1.496 1.665 1.737 1.866   
Prolacta Sample #2 1.127 1.328 1.367 1.588 1.625 1.680   
Prolacta Sample #3 1.114 1.279 1.559 1.580 1.658 1.645   
Prolacta Sample #4 0.963 1.248 1.508 1.626 1.646 1.635   
In-House Sample #1 0.944 1.301 1.507 1.529 1.621 1.692   
Average 1.042 1.288 1.487 1.597 1.657 1.703 1.927 
Standard Deviation 0.081 0.055 0.096 0.058 0.055 0.096   
% CV 7.8% 4.3% 6.5% 3.7% 3.3% 5.6%   












e Prolacta Sample #1 1.396 1.431 1.611 1.670 1.736 1.750   
Prolacta Sample #2 1.555 1.482 1.650 1.646 1.642 1.702   
Prolacta Sample #3 1.435 1.509 1.615 1.608 1.716 1.748   
Prolacta Sample #4 1.381 1.485 1.560 1.659 1.692 1.778   
In-House Sample #1 1.475 1.420 1.621 1.636 1.750 1.767   
Average 1.448 1.466 1.611 1.641 1.707 1.749 1.900 
Standard Deviation 0.070 0.062 0.044 0.032 0.040 0.029   
% CV 4.8% 4.2% 2.7% 2.0% 2.4% 1.7%   





Prolacta Sample #1 0.910 0.623 0.706 0.677 0.725 1.149   
Prolacta Sample #2 1.244 0.820 1.133 0.897 0.691 1.391   
Prolacta Sample #3 0.332 0.367 1.308 0.762 0.971 1.622   
Prolacta Sample #4 0.304 0.519 0.420 0.628 1.664 1.647   
In-House Sample #1 1.038 0.510 0.561 0.777 0.964 1.372   
Average 0.765 0.630 0.825 0.744 1.003 1.417 2.903 
Standard Deviation 0.427 0.350 0.361 0.203 0.440 0.307   
% CV 55.8% 55.6% 43.8% 27.3% 43.9% 21.7%   
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Table 10  
Optimal Breast Milk Dilutions for Each Kit 
ASSAY DILUTION 
Amphetamine Ultra 1:10 
Benzodiazepine Group 1:10 
Cocaine/BZE 1:5 
Cotinine 1:5 
Opiate Group 1:5 
Oxycodone/Oxymorphone 1:20 






























Linearity of Standards for the Amphetamine Ultra Assay 
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.744 1.752 1.748  100.00          
0.2 1.571  1.474 1.523  87.10  0.17 15.34 -0.70 1.91 
2 1.255 1.063 1.159  66.30  1.71 14.69 0.30 0.68 
5 0.979 0.869 0.924  52.86  4.89 2.12 0.70 0.11 
10 0.781  0.697 0.739  42.28  10.87 8.72 1.00 -0.31 
20 0.583  0.485 0.534  30.55  28.27 41.33 1.30 -0.82 
50 0.406  0.331 0.369  21.08  71.97 43.94 1.70 -1.32 
500 0.204  0.172 0.188  10.76  319.82 36.04 2.70 -2.12 
I-50: 6.07  ng/ml Slope: -1.23         
R= 0.9931   Intercept:  0.96         
         
Human Breast Milk (1:10 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.671 1.610 1.641  100.00         
2 1.618 1.570 1.594  97.17 1.12 43.99 0.30 3.53 
20 1.317  1.272 1.295  78.91 22.39 11.94 1.30 1.32 
50 1.016  1.060 1.038  63.27 63.88 27.77 1.70 0.54 
100 0.817  0.794 0.806  49.10 139.93 39.93 2.00 -0.04 
200 0.592  0.613 0.603  36.73 278.11 39.05 2.30 -0.54 
500 0.421  0.393 0.407  24.81 596.87 19.37 2.70 -1.11 
5000 0.177  0.144 0.161  9.78 2686.95 46.26 3.70 -2.22 
I-50: 133.29 ng/ml Slope: -1.70         
R= 0.9860   Intercept:  3.62         
Approximate 70-30% B/B0 Range: 40-350 ng/mL 


















Linearity of Standards for the Benzodiazepine Group Assay 
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.763 1.657 1.710  100.00         
0.2 1.409  1.349 1.379  80.64 0.18 8.66 -0.70 1.43 
1 1.325 1.072 1.199  70.09 0.62 37.77 0.00 0.85 
2 0.901 0.875 0.888  51.93 3.24 61.84 0.30 0.08 
5 0.751 0.721 0.736  43.04 6.93 38.59 0.70 -0.28 
20 0.512  0.621 0.567  33.13 17.03 14.86 1.30 -0.70 
100 0.326  0.279 0.303  17.69 100.83 0.83 2.00 -1.54 
500 0.187  0.140 0.164  9.56 456.85 8.63 2.70 -2.25 
I-50: 3.82  ng/ml Slope: -1.08         
R= 0.9932   Intercept:  0.63         
         
Milk (1:10 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.513 1.518 1.516  100.00         
2 1.334 1.314 1.324  87.36 1.11 44.40 0.30 1.93 
10 1.053  1.003 1.028  67.83 10.90 9.03 1.00 0.75 
20 0.992  0.824 0.908  59.91 21.13 5.66 1.30 0.40 
50 0.551  0.644 0.598  39.43 104.49 108.98 1.70 -0.43 
200 0.488  0.446 0.467  30.81 216.68 8.34 2.30 -0.81 
1000 0.242  0.252 0.247  16.30 1063.36 6.34 3.00 -1.64 
5000 0.139  0.159 0.149  9.83 3242.19 35.16 3.70 -2.22 
I-50: 45.76 ng/ml Slope: -1.20         
R= 0.9879   Intercept:  1.99         
Approximate 70-30% B/B0 Range: 10-200 ng/mL 


















Linearity of Standards for the Cocaine/BZE Assay 
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.795 1.792 1.794  100.00          
0.1 1.764  1.761 1.763  98.27  0.10 0.75 -1.00 4.04 
0.5 1.645  1.626 1.636  91.19  0.49 1.54 -0.30 2.34 
1 1.474 1.411 1.443  80.43  1.17 17.34 0.00 1.41 
2 1.394 1.254 1.324  73.82  1.67 16.41 0.30 1.04 
5 0.823 0.767 0.795  44.33  5.49 9.80 0.70 -0.23 
10 0.650  0.529 0.590  32.87  8.67 13.28 1.00 -0.71 
20 0.282  0.272 0.277  15.44  21.91 9.57 1.30 -1.70 
I-50: 4.43  ng/ml Slope: -2.45         
R= 0.9976   Intercept:  1.58         
         
Milk (1:5 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.631 1.611 1.621  100.00         
0.5 1.506  1.608 1.557  96.05 0.75 49.79 -0.30 3.19 
2.5 1.425  1.495 1.460  90.07 2.39 4.20 0.40 2.20 
5 1.411 1.412 1.412  87.08 3.40 32.03 0.70 1.91 
10 1.243  1.145 1.194  73.66 9.58 4.25 1.00 1.03 
25 0.989  0.996 0.993  61.23 18.77 24.92 1.40 0.46 
50 0.876  0.767 0.822  50.68 31.14 37.72 1.70 0.03 
100 0.260  0.255 0.258  15.89 229.02 129.02 2.00 -1.67 
I-50: 32.15 ng/ml Slope: -1.95         
R= 0.9689   Intercept:  2.95         
Approximate 70-30% B/B0 Range: 14-75 ng/mL 


















Linearity of Standards for the Cotinine Assay  
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 2.107 2.006 2.057  100.00         
0.05 1.962  1.880 1.921  93.41 0.01 70.11 -1.30 2.65 
0.1 1.923  1.766 1.845  89.69 0.06 41.78 -1.00 2.16 
0.5 1.666  1.475 1.571  76.37 0.92 83.67 -0.30 1.17 
1 1.404 1.309 1.357  65.96 3.82 281.52 0.00 0.66 
5 1.158 1.052 1.105  53.73 15.88 217.59 0.70 0.15 
100 1.023  0.997 1.010  49.11 26.59 73.41 2.00 -0.04 
1000 0.434  0.428 0.431  20.96 971.28 2.87 3.00 -1.33 
I-50: 24.08 ng/ml Slope: -0.83         
R= 0.9584   Intercept:  1.14         
         
Milk (1:5 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.824 1.875 1.850  100.00         
0.25 1.742  1.761 1.752  94.70 0.14 42.99 -0.60 2.88 
0.5 1.681  1.730 1.706  92.21 0.36 27.56 -0.30 2.47 
2.5 1.517  1.503 1.510  81.64 3.33 33.38 0.40 1.49 
5 1.410 1.423 1.417  76.59 6.69 33.79 0.70 1.19 
25 1.034  1.067 1.051  56.80 52.81 111.22 1.40 0.27 
500 0.580  0.575 0.578  31.22 587.95 17.59 2.70 -0.79 
5000 0.350  0.343 0.347  18.73 2731.71 45.37 3.70 -1.47 
I-50: 98.19 ng/ml Slope: -1.02         
R= 0.9904   Intercept:  2.02         
Approximate 70-30% B/B0 Range: 10-500 ng/mL 


















Linearity of Standards for the Opiate Group Assay  
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 2.348 2.441 2.395  100.00          
0.1 2.219  2.040 2.130  88.93  0.18 83.22 -1.00 2.08 
0.5 2.108  1.899 2.004  83.67  0.41 17.88 -0.30 1.63 
1 1.909 1.785 1.847  77.14  0.87 13.11 0.00 1.22 
2 1.923 1.748 1.836  76.65  0.91 54.40 0.30 1.19 
10 1.189  0.998 1.094  45.67  10.50 5.04 1.00 -0.17 
20 0.910  0.766 0.838  35.00  23.35 16.75 1.30 -0.62 
50 0.620  0.473 0.547  22.82  68.38 36.76 1.70 -1.22 
I-50: 7.69  ng/ml Slope: -1.28         
R= 0.9805   Intercept:  1.14         
         
Milk (1:5 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.964 1.857 1.911  100.00         
0.5 1.824  1.825 1.825  95.50 0.64 27.07 -0.30 3.05 
2.5 1.709  1.671 1.690  88.46 2.70 8.03 0.40 2.04 
5 1.667 1.589 1.628  85.21 4.05 18.99 0.70 1.75 
10 1.572  1.501 1.537  80.42 6.55 34.47 1.00 1.41 
50 0.936  0.882 0.909  47.58 56.04 12.09 1.70 -0.10 
100 0.705  0.628 0.667  34.89 118.56 18.56 2.00 -0.62 
250 0.452  0.452 0.452  23.66 258.15 3.26 2.40 -1.17 
I-50: 48.83 ng/ml Slope: -1.62         
R= 0.9944   Intercept:  2.74         
Approximate 70-30% B/B0 Range: 25-175 ng/mL 


















Linearity of Standards for the Oxycodone/Oxymorphone Assay 
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.685 1.586 1.636  100.00          
0.2 1.657  1.478 1.568  95.84  0.13 34.48 -0.70 3.14 
0.5 1.340  1.270 1.305  79.79  0.50 0.96 -0.30 1.37 
0.8 1.001  1.004 1.003  61.30  0.99 23.20 -0.10 0.46 
1 0.959 0.824 0.892  54.51  1.22 21.61 0.00 0.18 
2 0.483 0.413 0.448  27.39  2.90 45.25 0.30 -0.97 
5 0.237 0.190 0.214  13.05  5.82 16.32 0.70 -1.90 
10 0.198  0.207 0.203  12.38  6.09 39.12 1.00 -1.96 
I-50: 1.39  ng/ml Slope: -3.06         
R= 0.9706   Intercept:  0.44         
         
Milk (1:20 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.619 1.619 1.619  100.00         
4 1.376 1.376 1.376  84.99 3.46 13.61 0.60 1.73 
10 1.167  1.167 1.167  72.08 7.37 26.26 1.00 0.95 
16 0.823  0.823 0.823  50.83 17.84 11.47 1.20 0.03 
20 0.703  0.706 0.705  43.51 23.69 18.46 1.30 -0.26 
40 0.347  0.347 0.347  21.43 64.53 61.32 1.60 -1.30 
100 0.224  0.224 0.224  13.84 107.62 7.62 2.00 -1.83 
200 0.180  0.180 0.180  11.12 136.95 31.53 2.30 -2.08 
I-50: 18.42 ng/ml Slope: -2.39         
R= 0.9764   Intercept:  3.02         
Approximate 70-30% B/B0 Range: 10-40 ng/mL 


















Linearity of Standards for the THC Assay  
EIA Buffer 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.842 1.852 1.847  100.00          
0.05 1.637  1.708 1.673  90.55  0.04 22.04 -1.30 2.26 
0.1 1.489  1.425 1.457  78.88  0.10 3.29 -1.00 1.32 
0.2 1.205  1.072 1.139  61.64  0.25 23.58 -0.70 0.47 
0.3 1.077  0.995 1.036  56.09  0.31 4.46 -0.52 0.24 
0.5 0.775  0.806 0.791  42.80  0.54 8.98 -0.30 -0.29 
1 0.544 0.533 0.539  29.16  1.01 1.12 0.00 -0.89 
5 0.167 0.169 0.168  9.10  4.37 12.70 0.70 -2.30 
I-50: 0.40  ng/ml Slope: -2.23         
R= 0.9952   Intercept:  -0.88         
         
Milk (1:100 dilution) 
STD (ng/mL) A 1 A 2 A Avg. %B/B0 Backfit %Error  logCONC LOGIT 
0 1.801 1.795 1.798  100.00         
5 1.682 1.593 1.638  91.07 3.14 37.11 0.70 2.32 
10 1.326  1.367 1.347  74.89 10.76 7.57 1.00 1.09 
20 1.003  0.933 0.968  53.84 27.51 37.53 1.30 0.15 
30 0.819  0.824 0.822  45.69 38.13 27.10 1.48 -0.17 
50 0.770  0.801 0.786  43.69 41.35 17.30 1.70 -0.25 
100 0.343  0.312 0.328  18.21 144.03 44.03 2.00 -1.50 
500 0.178  0.120 0.149  8.29 354.98 29.00 2.70 -2.40 
I-50: 32.08 ng/ml Slope: -2.30         
R= .9770   Intercept:  3.47         
Approximate 70-30% B/B0 Range: 13-75 ng/mL 


















Matrix Interference of Breast Milk Compared to EIA Buffer When Diluted 
ASSAY/ CALIBRATOR Dilution 
EIA A  
(0 ng/mL) 




Amphetamine Ultra  
(d-Amphetamine) 
1:10 1.748 1.641 6% 
Benzodiazepine Group  
(Oxazepam) 
1:10 1.710 1.516 11% 
Cocaine/BZE  
(Benzoylecgonine) 
1:5 1.794 1.621 10% 
Cotinine  
(Cotinine) 
1:5 2.057 1.850 10% 
Opiate Group  
(Hydromorphone) 
1:5 2.395 1.911 20% 
Oxycodone/ Oxymorphone 
(Oxycodone) 
1:20 1.636 1.619 1% 
THC  
(∆9-THC-COOH) 
1:100 1.847 1.798 3% 




























Range of %B/B0 Values From the Second and Third Validations 









#2 AVG % CV MIN MAX 
Amphetamine 
Ultra 
74.17 76.82 74.98 72.67 74.66 1.73 72.67 76.82 
Benzodiazepine 
Group 
45.18 46.04 48.41 43.91 45.89 1.90 43.91 48.41 
Cocaine/BZE 80.12 82.26 85.43 85.54 83.34 2.63 80.12 85.54 
Cotinine 58.10 78.57 82.90 66.78 71.59 11.28 58.10 82.90 
Opiate Group 87.98 78.25 75.48 82.43 81.03 5.44 75.48 87.98 
Oxycodone/ 
Oxymorphone 
72.05 63.44 60.28 59.66 63.86 5.71 59.66 72.05 
THC 76.27 80.73 74.10 68.50 74.90 5.08 68.50 80.73 









AVG % CV MIN MAX 
Amphetamine 
Ultra 
71.48 74.85 73.34 68.84 72.13 2.59 68.84 74.85 
Benzodiazepine 
Group 
63.62 44.49 49.09 51.69 52.22 8.16 44.49 63.62 
Cocaine/BZE 44.55 41.84 34.53 39.26 40.05 4.26 34.53 44.55 
Cotinine 54.82 54.21 53.85 54.28 54.29 0.40 53.85 54.82 
Opiate Group 62.39 60.19 56.12 56.50 58.80 3.02 56.12 62.39 
Oxycodone/ 
Oxymorphone 
59.38 58.98 59.57 64.62 60.64 2.67 58.98 64.62 
THC 72.55 71.40 75.75 75.20 73.72 2.08 71.40 75.75 
Note: The %B/B0 for the drift run from validation #3 was 91.09%.  The drift passed, but the 
%B/B0 was noted to be unusually high.  When the THC calibr tors were analyzed again, the 
%B/B0 was 72.55%.  As this falls within the normal range for the calibrators used for this 
validation, this value has been reported in this table for comparison purposes. 
 


























2.431 1.937 1.981 2.3% 80% 81% 
Benzodiazepine 
Group 
1.948 1.102 0.941 14.6% 57% 48% 
Cocaine/BZE 1.969 1.261 1.126 10.7% 64% 57% 
Cotinine 2.774 1.888 1.792 5.1% 68% 65% 
Opiate Group 1.813 1.253 1.201 4.2% 69% 66% 
Oxycodone/ 
Oxymorphone 
2.516 1.778 1.875 5.5% 71% 75% 
THC 2.129 1.731 1.785 3.1% 81% 84% 



















Stability of Multi-Drug Calibrators in Human Breast Milk 
Group 4 Cutoff Standard 
  %B/B0 OF CUTOFF 
ASSAY Day 0 Day 2 Day 4 Day 25 Day 31 AVG. STD. 
DEV. 
% CV 
Amphetamine Ultra 65 81 63 70 67 69.1 7.2 10% 
Cotinine 70 57 58 53 50 57.4 7.7 13% 
Oxycodone/ 
Oxymorphone 
56 74 67 64 73 66.6 7.2 11% 
 
Group 5 Cutoff Standard 
  %B/B0 OF CUTOFF 
ASSAY Day 0 Day 2 Day 4 Day 25 Day 31 AVG. 
STD. 
DEV. % CV 
Benzodiazepine 
Group 
48 43 49 47 45 46.4 2.1 5% 
Cocaine/BZE 55 48 54 68 49 54.5 8.0 15% 
Opiate Group 54 54 54 64 57 56.7 4.1 7% 



























































































1.617 1.751 1.508 2.288 1.692 2.493 1.498 
1.679 1.708 1.492 2.182 1.633 2.444 1.578 
1.614 1.769 1.648 2.187 1.644 2.479 1.595 
1.723 1.844 1.501 2.278 1.754 2.456 1.690 
1.702 1.904 1.524 2.249 1.734 2.510 1.660 
1.640 1.850 1.726 2.196 1.605 2.411 1.519 
1.596 1.809 1.707 2.226 1.600 2.456 1.513 
1.608 1.749 1.672 2.191 1.527 2.457 1.547 
1.547 1.767 1.643 2.214 1.416 2.461 1.540 
1.681 1.794 1.730 2.207 1.394 2.453 1.653 
AVG. 1.641 1.795 1.615 2.222 1.600 2.462 1.579 
STD. DEV. 0.055 0.058 0.098 0.038 0.122 0.027 0.068 
NEG A 
Avg. 
1.748 1.981 1.898 2.900 1.808 2.492 1.801 





6.5% 10.4% 17.5% 30.5% 13.0% 1.2% 14.0% 
%B/B 0 STD 
(CO/NEG) 
73.1% 38.7% 56.4% 53.3% 66.1% 56.1% 60.7% 
%B/B 0 
(CO/AVG.) 
77.8% 42.7% 66.3% 69.6% 74.7% 56.8% 69.2% 
%B/B 0 
DIFF. 
6.5% 10.4% 17.5% 30.5% 13.0% 1.2% 14.0% 
Note: A = Absorbance Value 





































































1.577 1.767 1.401 1.823 1.711 2.346 1.513 
1.568 1.755 1.390 1.805 1.702 2.330 1.503 
1.559 1.756 1.383 1.795 1.696 2.313 1.494 
1.552 1.743 1.373 1.778 1.687 2.292 1.485 
1.543 1.727 1.365 1.766 1.680 2.285 1.476 
1.535 1.719 1.357 1.754 1.671 2.276 1.464 
1.526 1.705 1.347 1.737 1.664 2.254 1.455 
1.517 1.696 1.338 1.724 1.655 2.244 1.445 
1.510 1.756 1.690 1.714 1.650 2.229 1.436 
1.489 1.663 1.309 1.702 1.643 2.199 1.411 
AVG. 1.538 1.729 1.395 1.760 1.676 2.277 1.468 
STD. DEV. 0.028 0.033 0.107 0.041 0.023 0.046 0.032 
NEG A 
Avg. 
1.569 1.790 1.707 2.560 1.743 2.280 1.591 





2.0% 3.6% 22.4% 45.4% 4.0% 0.2% 8.4% 
%B/B 0 STD 
(CO/NEG) 
72.9% 38.1% 56.2% 45.7% 66.4% 54.8% 61.3% 
%B/B 0 
(CO/AVG.) 
74.4% 39.4% 68.8% 66.5% 69.1% 54.9% 66.4% 
%B/B 0 
DIFF. 
2.0% 3.6% 22.4% 45.4% 4.0% 0.2% 8.4% 








Drift Validation Data From Three Separate Validation Runs 


















1 1.590 1.081 67.99 1.616 1.121 69.37 68.68 0.98 1.42 
2 1.181 0.876 74.17 1.416 1.064 75.14 74.66 0.68 0.92 
3 1.420 1.015 71.48 1.421 1.046 73.61 72.54 1.51 2.08 
Benzodiazepine 
Group 
1 2.368 1.092 46.11 2.515 1.263 50.22 48.17 2.90 6.02 
2 1.618 0.731 45.18 1.848 0.867 46.92 46.05 1.23 2.67 
3 1.813 1.154 63.62 1.924 1.048 54.47 59.05 6.47 10.96 
Cocaine/BZE 
1 1.684 1.147 68.11 1.705 1.269 74.43 71.27 4.47 6.27 
2 1.454 1.165 80.12 1.449 1.180 81.44 80.78 0.93 1.15 
3 1.714 1.004 58.55 1.775 1.127 63.49 61.02 3.50 5.73 
Cotinine 
1 2.441 1.284 52.60 2.385 1.355 56.81 54.71 2.98 5.44 
2 2.976 1.729 58.10 2.961 1.801 60.82 59.46 1.93 3.24 
3 3.274 1.795 54.82 3.115 1.898 60.93 57.87 4.32 7.47 
Opiate Group 
1 1.780 1.060 59.55 1.604 0.983 61.28 60.42 1.23 2.03 
2a 1.423 1.252 87.98 1.378 1.178 85.49 86.73 1.77 2.04 
2b 1.581 1.144 72.36 1.407 1.177 83.65 78.01 7.99 10.24 
3 1.467 0.915 62.39 1.609 0.841 52.27 57.33 7.16 12.49 
Oxycodone/ 
Oxymorphone 
1 2.499 0.801 32.05 2.344 0.892 38.05 35.05 4.24 12.11 
2 2.487 1.792 72.05 2.392 1.766 73.83 72.94 1.25 1.72 
3 2.083 1.237 59.38 2.059 1.258 61.10 60.24 1.22 2.02 
THC 
1 2.036 1.160 56.97 1.974 1.305 66.11 61.54 6.46 10.50 
2 1.749 1.334 76.27 1.169 0.998 85.37 80.82 6.43 7.96 
3 1.481 1.349 91.09 1.415 1.269 89.68 90.38 0.99 1.10 
Note: A = Absorbance Value 













DEV. % CV 
Amphetamine Ultra 
1-1 1.649 0.07 4.02 1.159 0.05 4.26 
1-2 1.320 0.05 3.69 1.019 0.05 4.53 
2-1 1.432 0.07 5.00 1.095 0.07 6.16 
2-2 1.287 0.07 5.39 0.963 0.07 7.33 
3-1 1.379 0.03 2.29 1.046 0.04 4.02 
3-2 1.491 0.06 3.71 1.113 0.04 3.21 
Benzodiazepine Group 
1-1 2.431 0.06 2.46 1.187 0.06 5.24 
1-2 2.377 0.04 1.59 1.155 0.08 7.01 
2-1 2.009 0.08 4.20 0.868 0.08 8.94 
2-2 2.120 0.11 5.02 0.822 0.04 4.72 
3-1 1.730 0.02 1.32 0.801 0.04 5.55 
3-2 1.774 0.05 2.74 0.816 0.03 3.92 
Cocaine/BZE 
1-1 1.603 0.07 4.58 1.240 0.08 6.86 
1-2 1.619 0.15 8.98 1.219 0.14 11.44 
2-1 1.283 0.11 8.79 1.074 0.09 8.70 
2-2 1.316 0.14 10.92 1.130 0.13 11.56 
3-1 1.273 0.05 3.80 0.514 0.03 5.42 
3-2 1.242 0.07 5.78 0.486 0.03 5.91 
Cotinine 
1-1 2.325 0.12 5.30 1.282 0.05 3.98 
1-2 2.138 0.13 6.29 1.294 0.07 5.51 
2-1 3.009 0.07 2.44 2.382 0.03 1.25 
2-2 3.012 0.05 1.61 2.404 0.10 4.34 
3-1 3.189 0.09 2.79 1.795 0.06 3.19 
3-2 3.323 0.13 3.82 1.855 0.10 5.13 
Opiate Group 
1-1 1.859 0.09 4.86 1.154 0.08 7.30 
1-2 1.829 0.12 6.30 1.201 0.07 5.43 
2-1 1.545 0.06 4.10 1.445 0.08 5.48 
2-2 1.223 0.05 4.21 1.107 0.11 9.53 
3-1 1.452 0.08 5.25 0.864 0.05 5.34 
3-2 1.559 0.11 6.87 0.876 0.07 7.70 
Oxycodone/ 
Oxymorphone 
1-1 2.484 0.06 2.48 0.787 0.03 4.32 
1-2 2.399 0.06 2.39 0.772 0.04 4.70 
2-1 2.360 0.10 4.14 2.179 0.14 6.38 
2-2 1.436 0.08 5.59 1.223 0.10 8.28 
3-1 2.012 0.07 3.47 1.296 0.03 2.31 
3-2 2.116 0.02 1.16 1.348 0.03 2.33 
THC 
1-1 2.032 0.06 2.75 1.284 0.07 5.67 
1-2 2.049 0.07 3.22 1.294 0.05 4.02 
2-1 1.718 0.08 4.79 1.663 0.10 5.86 
2-2 1.411 0.08 6.02 1.336 0.11 8.15 
3-1 1.458 0.07 4.98 1.131 0.03 2.74 
3-2 1.575 0.09 5.50 1.232 0.05 4.17 
Note: Runs are categorized by validation number, then run number. 
Note: A = Absorbance Value 




Accuracy Validation Data for Three Separate Validaton Runs 
    Average A Correct Results (%) 
ASSAY RUN NEG 
A 










1 1.466 0.901 1.142 0.987 0.916 100 67 33 
2 1.760 1.279 1.426 1.176 1.005 100 22 100 
3 1.641 1.154 1.259 1.035 0.888 100 0 100 
Benzodiazepine 
Group 
1 2.303 1.075 0.753 0.828 0.721 0 0 100 
2 1.963 0.862 1.036 0.835 0.688 100 22 100 
3 2.033 1.097 1.281 0.991 0.930 100 17 100 
Cocaine/BZE 
1 1.429 0.956 1.072 0.956 0.739 89 44 100 
2 1.949 1.099 1.302 0.895 0.494 78 11 100 
3 1.316 0.498 0.807 0.500 0.327 100 33 100 
Cotinine 
1 2.363 1.324 1.900 1.850 1.892 0 0 0 
2 3.164 2.113 2.335 2.016 1.843 100 11 100 
3 3.258 1.753 1.918 1.581 1.473 100 0 100 
Opiate Group 
1 2.039 1.045 1.675 1.641 1.593 0 0 0 
2 1.389 1.145 1.169 0.929 0.780 56 0 100 
3 1.586 0.888 1.002 0.857 0.721 100 50 100 
Oxycodone/ 
Oxymorphone 
1 2.622 0.964 1.487 1.185 0.897 100 100 89 
2 2.330 1.390 1.828 1.377 1.047 100 44 89 
3 2.007 1.231 1.657 1.280 0.948 100 100 100 
THC 
1 1.742 1.036 0.802 0.978 0.884 0 11 100 
2 1.930 1.322 1.561 1.305 1.246 100 22 100 
3 1.375 1.061 1.229 1.054 0.933 100 50 100 
Note: A = Absorbance Value 
 




Final Kit Calibrators, Dilutions, and Cutoff Levels 
KIT CALIBRATOR DILUTION 
CUTOFF 
LEVEL 
Amphetamine Ultra d-Amphetamine 1:10 50 ng/mL 
Benzodiazepine Group Oxazepam 1:10 50 ng/mL 
Cocaine/BZE Benzoylecgonine (BZE) 1:5 50 ng/mL 
Cotinine Cotinine 1:5 50 ng/mL 
Opiate Group Hydromorphone 1:5 50 ng/mL 
Oxycodone/ Oxymorphone Oxycodone 1:20 30 ng/mL 











































































Standard Curves in EIA Buffer and Human Breast Milk for the Amphetamine Ultra Assay 
Amphetamine Ultra
d-Amphetamine Concentration (ng/mL)










100 EIA, I-50: 6.07ng/mL

























Standard Curves in EIA Buffer and Human Breast Milk for the Benzodiazepine Group Assay 
Benzodiazepine Group
Oxazepam Concentration (ng/mL)










100 EIA, I-50: 3.82ng/mL

























Standard Curves in EIA Buffer and Human Breast Milk for the Cocaine/BZE Assay 
Cocaine/BZE
BZE Concentration (ng/mL)





































Standard Curves in EIA Buffer and Human Breast Milk for the Cotinine Assay 
Cotinine
Cotinine Concentration (ng/mL)










100 EIA, I-50: 24.08ng/mL

























Standard Curves in EIA Buffer and Human Breast Milk for the Opiate Group Assay 
Opiate Group
Hydromorphone Concentration (ng/mL)










100 EIA, I-50: 7.69ng/mL

























Standard Curves in EIA Buffer and Human Breast Milk for the Oxycodone/Oxymorphone Assay 
Oxycodone/Oxymorphone
Oxycodone Concentration (ng/mL)










100 EIA, I-50: 1.39ng/mL

























Standard Curves in EIA Buffer and Human Breast Milk for the THC kit 
THC
delta9-THC-COOH Concentration (ng/mL)










100 EIA, I-50: 0.40ng/mL
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Appendix C  
ELISA Results for Multi-Drug and Single Drug Calibrator Comparison 










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 04/05/2012
Negative and Cutoff Calibrators were prepared 04/05/2012
Kit, Plate, and Reagent Lot Data
Date: 04/05/2012
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Appendix D  
ELISA Results for Variability Between Single and Multiple Readings 










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0055B* OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
*This kit lot number was found to be defective.  No results could be obtained.
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/23/2012










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 04/06/2012
Negative and Cutoff Calibrators were prepared 04/06/2012
Kit, Plate, and Reagent Lot Data
Date: 03/23/2012
Kit, Plate, and Reagent Lot Data
Date: 04/06/2012
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ELISA Results for Validation #1 










Kit # AUF-0046 BGF-0060 BZF-0073 CTI-0031 MOF-0055 OXF-0036 TCF-0054
Kit Exp. Date 1/8/2013 12/28/2012 11/9/2012 4/23/2012 1/5/2014 1/16/2013 12/26/2012
Plate # 111214 111205 111121F 1102211 120105F 110506F 111221
Plate Exp. 
Date
12/14/2013 12/5/2013 11/21/2013 2/21/2013 1/5/2014 5/6/2013 12/21/2013
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 24 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 035 049 053 032 043 028 043
CONJ Exp. 1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 02/08/2012










Kit # AUF-0046 BGF-0060 BZF-0073 CTI-0031 MOF-0055 OXF-0036 TCF-0054
Kit Exp. Date 1/8/2013 12/28/2012 11/9/2012 4/23/2012 1/5/2014 1/16/2013 12/26/2012
Plate # 111214 111205 111121F 1102211 120105F 110506F 111221
Plate Exp. 
Date
12/14/2013 12/5/2013 11/21/2013 2/21/2013 1/5/2014 5/6/2013 12/21/2013
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 24 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 035 049 053 032 043 028 043
CONJ Exp. 1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 02/09/2012
Negative and Cutoff Calibrators were prepared 02/09/2012
Kit, Plate, and Reagent Lot Data
Date: 02/08/2012
Kit, Plate, and Reagent Lot Data
Date: 02/09/2012
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ELISA Results for Validation #2 










Kit # AUF-0046 BGF-0060 BZF-0073 CTI-0031 MOF-0055 OXF-0036 TCF-0054
Kit Exp. Date 1/8/2013 12/28/2012 11/9/2012 4/23/2012 1/5/2014 1/16/2013 12/26/2012
Plate # 111214 111205 111121F 1102211 120105F 110506F 111221
Plate Exp. 
Date
12/14/2013 12/5/2013 11/21/2013 2/21/2013 1/5/2014 5/6/2013 12/21/2013
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 24 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 035 049 053 032 043 028 043
CONJ Exp. 1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/06/2012










Kit # AUF-0046 BGF-0060 BZF-0073 CTI-0031 MOF-0055 OXF-0036 TCF-0054
Kit Exp. Date 1/8/2013 12/28/2012 11/9/2012 4/23/2012 1/5/2014 1/16/2013 12/26/2012
Plate # 111214 111205 111121F 1102211 120105F 110506F 111221
Plate Exp. 
Date
12/14/2013 12/5/2013 11/21/2013 2/21/2013 1/5/2014 5/6/2013 12/21/2013
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 24 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 035 049 053 032 043 028 043
CONJ Exp. 1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/07/2012
Negative and Cutoff Calibrators were prepared 03/07/2012
Kit, Plate, and Reagent Lot Data
Date: 03/06/2012
Kit, Plate, and Reagent Lot Data
Date: 03/07/2012










Kit # AUF-0046 BGF-0060 BZF-0073 CTI-0031 MOF-0055 OXF-0036 TCF-0054
Kit Exp. Date 1/8/2013 12/28/2012 11/9/2012 4/23/2012 1/5/2014 1/16/2013 12/26/2012
Plate # 111214 111205 111121F 1102211 120105F 110506F 111221
Plate Exp. 
Date
12/14/2013 12/5/2013 11/21/2013 2/21/2013 1/5/2014 5/6/2013 12/21/2013
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 24 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 035 049 053 032 043 028 043
CONJ Exp. 1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/08/2012
Negative and Cutoff Calibrators were prepared 03/08/2012
Kit, Plate, and Reagent Lot Data
Date: 03/08/2012
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ELISA Results for Validation #3 










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/27/2012










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/28/2012
Negative and Cutoff Calibrators were prepared 03/28/2012
Kit, Plate, and Reagent Lot Data
Date: 03/27/2012
Kit, Plate, and Reagent Lot Data
Date: 03/28/2012










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/29/2012
Negative and Cutoff Calibrators were prepared 03/29/2012
Kit, Plate, and Reagent Lot Data
Date: 03/29/2012
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ELISA Results for Sample Analysis 










Kit # AUF-0047B BGF-0061B BZF-0078B CTI-0034 MOF-0056B OXF-0037B TCF-0055B
Kit Exp. Date 1/30/2013 1/23/2013 2/22/2013 7/10/2012 2/22/2013 1/16/2013 2/9/2013
Plate # 120119 120119 120116FAM 1102211 120213F 111103F 120208
Plate Exp. 
Date
1/19/2014 1/19/2014 1/16/2014 2/21/2013 2/13/2014 11/3/2013 2/8/2014
C/O & NEG 
lot #
111212-WB 110811-WB 111110-WB 026 110715-WB 120117-WB 110826-WB
C/O & NEG 
Exp. Date
1/8/2013 12/28/2012 11/9/2012 - 1/10/2013 1/16/2013 12/26/2012
CONJ lot # 036 050 055 034 044 028 044
CONJ Exp. 1/30/2013 1/23/2013 2/22/2013 - 2/22/2013 1/16/2013 2/9/2013
Acid Stop, EIA Buffer, K-Blue, Distilled Water, and Neogen Wash Buffer were prepared on 03/30/2012
Negative and Cutoff Calibrators were prepared 03/30/2012
Kit, Plate, and Reagent Lot Data
Date: 03/30/2012
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